[go: up one dir, main page]

EP0541407A1 - Nitrogen containing bicyclic derivatives, method for their preparation and pharmaceutical compositions containing them - Google Patents

Nitrogen containing bicyclic derivatives, method for their preparation and pharmaceutical compositions containing them Download PDF

Info

Publication number
EP0541407A1
EP0541407A1 EP92402631A EP92402631A EP0541407A1 EP 0541407 A1 EP0541407 A1 EP 0541407A1 EP 92402631 A EP92402631 A EP 92402631A EP 92402631 A EP92402631 A EP 92402631A EP 0541407 A1 EP0541407 A1 EP 0541407A1
Authority
EP
European Patent Office
Prior art keywords
formula
carbonyl
compounds
pharmaceutically acceptable
epimers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP92402631A
Other languages
German (de)
French (fr)
Other versions
EP0541407B1 (en
Inventor
Michel Vincent
Georges Remond
Bernard Portevin
Yolande Herve
Jean Lepagnol
Guillaume De Nanteuil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Publication of EP0541407A1 publication Critical patent/EP0541407A1/en
Application granted granted Critical
Publication of EP0541407B1 publication Critical patent/EP0541407B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Definitions

  • the present invention relates to new nitrogenous bicyclic derivatives, their preparation process and the pharmaceutical compositions containing them.
  • neuropeptides such as vasopressin (AVP) or thyrotropin releasing hormone (TRH) which also exert memory-enhancing effects by playing a neuromodulation role. in addition to their peripheral or endocrine role (Science, 211 , 601, 1981).
  • AVP vasopressin
  • TRH thyrotropin releasing hormone
  • the compounds of the present invention apart from the fact that they are new, have been shown to be particularly interesting by the intensity and the duration of their properties in inhibiting prolyl endopeptidase and therefore in avoiding the degradation of the natural neuropeptides involved in memory functions. .
  • Their activity is greater both in vitro and in vivo than that of compounds described in the prior art such as, for example, the compounds described in patents EP 321,956 and EP 345,428 as inhibitors of PPCE. It is also clearly superior to that of reference nootropes also known for inhibiting the activity of PPCE, for example the compounds described in patent EP 288 685.
  • the compounds of the invention are therefore useful for the prevention and treatment on the one hand of behavioral disorders, in particular of memory, associated with aging and acute or chronic neuronal degenerative diseases and on the other hand of mental disorders associated with l and depression.
  • the invention relates more particularly to new nitrogenous bicyclic derivatives, corresponding to the general formula (I): in which : A represents with the carbon and nitrogen atoms to which it is attached any of the following heterocyclics: B represents with the nitrogen atom to which it is attached any one of the following heterocycles: R1 represents a linear or branched (C1-C6) alkoxy, benzyloxy, phenoxy, linear or branched (C1-C6) alkyl, linear or branched (C1-C6) alkenyl or cycloalkyl (C3-C7) group, each of the alkyl groups, alkenyl or cycloalkyl being optionally substituted by one or more groups, identical or different: phenyl, naphthyl, cycloalkyl (C3-C7), phenylcycloalkyl (C3-C7), trifluoromethyl, dicycloalkyl (C3-C7) methylthio, (in which R2 and R
  • hydrochloric sulfuric, tartaric, maleic, fumaric, methane sulphonic, camphoric acids, etc.
  • the invention also extends to the process for the preparation of the compounds of formula (I) characterized in that an acid of formula (II) is reacted, from which the isomers have optionally been separated by a conventional separation technique: in which A has the same meaning as in formula (I) and R′1 represents a linear or branched (C1-C6) alkoxy or benzyloxy group, on an amine of formula (III), the isomers of which are optionally separated by a conventional separation technique, according to a peptide coupling technique such as that described by W. KONIG and R.
  • the compounds of the invention have very advantageous pharmacological properties. They strongly inhibit prolyl-endopeptidase activity which makes them useful for the treatment of memory and cognitive disorders and neurobehavioral disorders associated with aging and degenerative diseases of the system. nervous, acute or chronic such as Alzheimer's, Pick's, Korsakoff's disease, stroke, spinal trauma or amyotrophic lateral sclerosis. They are similarly useful in the treatment of mental disorders associated with anxiety and depression.
  • the present invention also relates to pharmaceutical compositions containing as active principle at least one compound of general formula (I) or one of its addition salts with a pharmacologically acceptable acid, alone or in combination with one or more excipients or inert vehicles , non-toxic.
  • compositions according to the invention mention may be made more particularly of those which are suitable for oral, parenteral, nasal administration, simple or coated tablets, sublingual tablets, sachets, packages, capsules, glossettes, tablets, suppositories, creams, ointments, dermal gels, etc.
  • the dosage varies according to the age and weight of the patient, the nature and severity of the condition and the route of administration.
  • the unit dosage ranges from 0.5 to 100 mg for a treatment in 1 to 3 doses per 24 hours.
  • the expected product is obtained by reacting potassium cyanide on the compound described in the previous stage in ethanol / water medium. Yield : 73% Boiling point : 114-117 ° C (17 mm / Hg)
  • the expected product is obtained using the process described in Preparation B.
  • the expected product is obtained by saponification of the compound described in the previous stage. Yield : 92% Melting point : 95 ° C
  • the expected product is obtained by catalytic hydrogenation in an ethanolic medium of the compound described in stage A of preparation A using palladium on carbon as catalyst then saponification.
  • Efficiency 90% Melting point : 72 ° C
  • the expected product is obtained by proceeding as in preparation B from 3-phenyl-3-trifluoromethylpropanol (itself obtained by reduction of ethyl 3-phenyl-3-trifluoromethylpropanoate).
  • Infrared (nujol) ⁇ CO 1728 cm ⁇ 1
  • the expected product is obtained by proceeding as in preparation B from 4-phenyl-4-trifluoromethylbutanol (itself obtained by reduction of the compound obtained in preparation J). Boiling point : 106-110 ° C (16 mm / Hg)
  • the expected product is obtained by proceeding as in preparation B from 4-cyclopentyl-4-trifluoromethylbutanol.
  • the expected product is obtained according to the same process as that described in Example 1 but using the (3R) isomer of 2-aza-2-tertbutyloxycarbonyl bicyclo [2.2.2] octane-3-carboxylic acid with the place of the isomer (3S). Melting point : 150-152 ° C
  • Elementary microanalysis : VS % H% NOT % calculated 66.20 9.15 9.08 find 66.93 9.15 9.18
  • Examples 3 to 6 were obtained according to the process described in Example 1 using the corresponding known starting materials.
  • the expected product is obtained according to the same process as that described in Example 1 but using 4-phenylbutyric acid and the product obtained in Stage A. It is purified by chromatography on silica using a mixture of elution solvents dichloromethane / methanol (95/5) and crystallized from an acetone-isopropyl oxide mixture. Melting point : 77 ° C
  • Elementary microanalysis : VS % H% NOT % calculated 74.54 8.53 7.90 find 74.71 8.56 7.93
  • Examples 8 to 34 were obtained according to the process described in Example 7 using the corresponding starting materials known or described in preparations A to N.
  • Examples 35 to 43 were obtained according to the method described in Example 1 but using the corresponding starting materials.
  • Examples 44 and 45 were prepared by separation of the isomers of Example 26 by chromatography on silica gel using a 70/30 toluene-ethyl acetate mixture as eluent.
  • the isomers were named ⁇ and ⁇ in order of leaving the column.
  • Example 46 was prepared according to the method described in Example 7.
  • Examples 47 to 58 were synthesized according to the method described in Example 7 using the corresponding starting materials.
  • the compounds of Examples 31, 47, 49, 51, 53, 55, 57 and 32, 48, 50, 52, 54, 56, 58 can also be obtained from 2-phenylcycloprop-1-yl carboxylic acids of respective configuration (1S, 2S) and (1R, 2R) prepared according to the method described in "Optical resolution for Chemical compounds" (vol.2, part I / Optical Resolution information center, Manhattan College, Riverdale - NY 10471, USA).
  • Prolylendopeptidase is isolated from Flavobacterium meningosepticum.
  • the enzyme substrate is Z-Gly-Pro-pNitroaniline.
  • a mixture of 0.1 M phosphate buffer (pH 7; 0.99 ml), 2 M substrate (0.25 ml) and a solution of the inhibitor compound to be tested (0.01 ml) is incubated at 37 °. C for 5 minutes. Then 0.1 ml of a prolylendopeptidase solution (0.5 U / ml) is added and the mixture is left for 10 minutes at 37 ° C. The enzymatic reaction is stopped by adding 2 ml of a solution of Triton X-100-1 M acetate buffer (pH 4). After standing at room temperature, the absorbance is measured at 410 nm.
  • a control measurement is carried out by replacing the solution of the compound to be tested with the same volume of phosphate buffer. The percentage inhibition of the enzyme is calculated from this control measurement. For each compound tested, the concentration inhibiting prolylendopeptidase by 50% (IC50) is determined.
  • the compounds of the invention were compared with the two reference compounds known for their strong prolylendopeptidase inhibiting activity and described initially for this purpose: ONO1603 (EP 345 428) and N- (4-phenylbutanoyl) -L-thiaprolylpyrrolidineimide (example 3: EP 321 956) called ZERIA below.
  • the derivatives of the invention exert a strong inhibitory activity on prolylendopeptidase, superior to the reference compounds as indicated in the table of IC50:
  • An extract of the cerebral cortex is prepared by grinding the tissue in a phosphate buffer (NaH2PO4 25 mM; DTT 2 mM; EDTA-2K 0.5 mM) at a rate of 5 ml / g.
  • a phosphate buffer NaH2PO4 25 mM; DTT 2 mM; EDTA-2K 0.5 mM
  • test product is either added to the cortex extract before the first incubation (determination of the IC50 in vitro) or administered by the IP route 30 minutes before the preparation of the tissue extract.
  • the compounds of the invention strongly inhibit prolylendopeptidase from the rat cerebral cortex both in vitro and after administration in vivo. Again, this activity is much higher than that of the reference compounds.
  • the duration of action of the compounds with respect to the in vivo inhibition of prolylendopeptidase in the cerebral cortex of the Rat was estimated according to the same methodology as in Example 58, by administering the compounds by the IP route. studied at various times before the preparation of the tissue extract. The time for which the inhibitory effect is equal to 50% of the maximum effect (measured at 30 minutes) has been calculated (t 1/2).
  • the oral bioavailability of the compounds of the invention was estimated by administering them by the IP or oral route 30 minutes or 60 minutes before the measurement of the inhibitory effect.
  • the oral bioavailability index (IBO) was determined by dividing the inhibitory effect (%) measured after oral administration by that measured after IP administration.
  • the most active compounds of the invention exert their effects according to a duration of cerebral action much longer than that of the reference compounds and with a much greater oral bioavailability, which gives them a preponderant therapeutic interest.
  • Example 1 Composed of Example 1 10g Hydroxypropyl cellulose 2 g Wheat starch 10g Lactose 100g Magnesium stearate 3 g Talc 3 g

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The invention relates to the compounds of formula (I): <IMAGE> (I) in which: A represents, with the nitrogen and carbon atoms to which it is bound, a heterocycle, B represents, with the nitrogen atom to which it is bound, a heterocycle, R1 represents alkoxy, benzyloxy, phenoxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted cycloalkyl, their enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid, medicinal products containing the same.

Description

La présente invention concerne de nouveaux dérivés bicycliques azotés, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.The present invention relates to new nitrogenous bicyclic derivatives, their preparation process and the pharmaceutical compositions containing them.

Le vieillissement de la population par allongement de la durée de vie rend de plus en plus important le problème du vieillissement cérébral et des démences séniles liées à l'âge. C'est pourquoi, la recherche de nouveaux composés thérapeutiques pouvant s'opposer aux déficits de la mémoire et aux troubles neuropsychocomportementaux de la sénescence est devenue prioritaire.The aging of the population by lengthening the lifespan makes more and more important the problem of cerebral aging and senile dementias linked to age. This is why the search for new therapeutic compounds capable of opposing memory deficits and neuropsychobehavioral disorders of senescence has become a priority.

A côté des neurotransmetteurs classiques (acétylcholine, norepinephrine) impliqués dans les fonctions de mémoire, il y a des neuropeptides tels que la vasopressine (AVP) ou la thyrotropin releasing hormone (TRH) qui exercent également des effets facilitateurs mnésiques en jouant un rôle de neuromodulation en plus de leur rôle périphérique ou endocrinien (Science, 211, 601, 1981).Besides the classic neurotransmitters (acetylcholine, norepinephrine) involved in memory functions, there are neuropeptides such as vasopressin (AVP) or thyrotropin releasing hormone (TRH) which also exert memory-enhancing effects by playing a neuromodulation role. in addition to their peripheral or endocrine role (Science, 211 , 601, 1981).

Récemment, des études ont montré que les taux cérébraux de ces peptides diminuent significativement chez les patients atteints de démence sénile (Neurobiology, 36, 1133, 1986).Recently, studies have shown that brain levels of these peptides decrease significantly in patients with senile dementia (Neurobiology, 36 , 1133, 1986).

Encore plus récemment, il a été observé que l'activité de la prolylendopeptidase, enzyme-clé du catabolisme de ces peptides, augmente considérablement (+ 100 %) dans le cerveau des malades d'Alzheimer (Experientia, 46, 94, 1990). C'est pourquoi, il a été suggéré et démontré que des inhibiteurs de la prolyl-endopeptidase peuvent s'opposer aux déficits de la mémoire en favorisant l'effet promnésique de certains neuropeptides et notamment de la vasopressine. Ces résultats ont été observés notamment lors d'amnésie expérimentale à la scopolamine. Pour les composés inhibiteurs étudiés, une excellente corrélation entre l'effet inhibiteur de la prolyl-endopeptidase et l'effet facilitateur de l'apprentissage a été rapportée (EP 321 956).Even more recently, it has been observed that the activity of prolylendopeptidase, the key enzyme in the catabolism of these peptides, increases considerably (+ 100%) in the brains of Alzheimer's patients (Experientia, 46 , 94, 1990). This is why, it has been suggested and demonstrated that inhibitors of prolylendopeptidase can oppose memory deficits by promoting the promnesic effect of certain neuropeptides and in particular vasopressin. These results have been observed in particular during experimental scopolamine amnesia. For the inhibitory compounds studied, an excellent correlation between the inhibitory effect of prolylendopeptidase and the effect facilitating learning has been reported (EP 321,956).

Il était donc particulièrement intéressant de synthétiser de nouveaux composés possédant une activité inhibitrice de la prolylendopeptidase (ou post-prolyl cleaving enzyme : PPCE).It was therefore particularly interesting to synthesize new compounds having a prolylendopeptidase (or post-prolyl cleaving enzyme: PPCE) inhibitory activity.

Les composés de la présente invention, outre le fait qu'ils soient nouveaux, se sont montrés particulièrement intéressants par l'intensité et la durée de leurs propriétés à inhiber la prolyl-endopeptidase donc à éviter la dégradation des neuropeptides naturels impliqués dans les fonctions mnésiques. Leur activité est supérieure tant in vitro qu'in vivo à celle de composés décrits dans l'art antérieur comme par exemple les composés décrits dans les brevets EP 321 956 et EP 345 428 en tant qu'inhibiteurs de PPCE . Elle est également nettement supérieure à celle de nootropes de référence connus également pour inhiber l'activité de la PPCE comme par exemple les composés décrits dans le brevet EP 288 685.The compounds of the present invention, apart from the fact that they are new, have been shown to be particularly interesting by the intensity and the duration of their properties in inhibiting prolyl endopeptidase and therefore in avoiding the degradation of the natural neuropeptides involved in memory functions. . Their activity is greater both in vitro and in vivo than that of compounds described in the prior art such as, for example, the compounds described in patents EP 321,956 and EP 345,428 as inhibitors of PPCE. It is also clearly superior to that of reference nootropes also known for inhibiting the activity of PPCE, for example the compounds described in patent EP 288 685.

Les composés de l'invention sont donc utiles pour la prévention et le traitement d'une part des troubles comportementaux, notamment de la mémoire, associés au vieillissement et aux maladies dégénératives neuronales aigües ou chroniques et d'autre part des troubles psychiques associés à l'anxiété et la dépression.The compounds of the invention are therefore useful for the prevention and treatment on the one hand of behavioral disorders, in particular of memory, associated with aging and acute or chronic neuronal degenerative diseases and on the other hand of mental disorders associated with l and depression.

L'invention concerne plus particulièrement de nouveaux dérivés bicycliques azotés, répondant à la formule générale (I) :

Figure imgb0001

dans laquelle :
   A représente avec les atomes de carbone et d'azote auquel il est attaché l'un quelconque des hétérocycliques suivants :
Figure imgb0002
Figure imgb0003
Figure imgb0004
Figure imgb0005
Figure imgb0006
   B représente avec l'atome d'azote auquel il est attaché l'un quelconque des hétérocycles suivants :
Figure imgb0007
Figure imgb0008
Figure imgb0009
Figure imgb0010
   R₁ représente un groupement alkoxy (C₁-C₆) linéaire ou ramifié, benzyloxy, phénoxy, alkyle (C₁-C₆) linéaire ou ramifié, alkényle (C₁-C₆) linéaire ou ramifié ou cycloalkyle (C₃-C₇), chacun des groupements alkyle, alkényle ou cycloalkyle étant éventuellement substitué par un ou plusieurs groupements, identiques ou différents :
      phényle, naphtyle, cycloalkyle (C₃-C₇), phénylcycloalkyle (C₃-C₇), trifluorométhyle, dicycloalkyle (C₃-C₇) méthylthio,
Figure imgb0011
(dans lequel R₂ et R₃, identiques ou différents, représentent un atome d'hydrogène, un groupement phényle, benzyle ou dicycloalkyle (C₃-C₇) méthyle),
Figure imgb0012
(dans lequel
      R₄ représente un groupement phényle, cycloalkyle (C₃-C₇) ou dicycloalkyle (C₃-C₇) méthyle,
      R₅ représente un atome d'hydrogène, un groupement phényle, cycloalkyle (C₃-C₇) ou trifluorométhyle),The invention relates more particularly to new nitrogenous bicyclic derivatives, corresponding to the general formula (I):
Figure imgb0001
in which :
A represents with the carbon and nitrogen atoms to which it is attached any of the following heterocyclics:
Figure imgb0002
Figure imgb0003
Figure imgb0004
Figure imgb0005
Figure imgb0006
B represents with the nitrogen atom to which it is attached any one of the following heterocycles:
Figure imgb0007
Figure imgb0008
Figure imgb0009
Figure imgb0010
R₁ represents a linear or branched (C₁-C₆) alkoxy, benzyloxy, phenoxy, linear or branched (C₁-C₆) alkyl, linear or branched (C₁-C₆) alkenyl or cycloalkyl (C₃-C₇) group, each of the alkyl groups, alkenyl or cycloalkyl being optionally substituted by one or more groups, identical or different:
phenyl, naphthyl, cycloalkyl (C₃-C₇), phenylcycloalkyl (C₃-C₇), trifluoromethyl, dicycloalkyl (C₃-C₇) methylthio,
Figure imgb0011
(in which R₂ and R₃, identical or different, represent a hydrogen atom, a phenyl, benzyl or dicycloalkyl (C₃-C₇) methyl group),
Figure imgb0012
(in which
R₄ represents a phenyl, cycloalkyl (C₃-C₇) or dicycloalkyl (C₃-C₇) methyl group,
R₅ represents a hydrogen atom, a phenyl, cycloalkyl (C₃-C₇) or trifluoromethyl group),

à la condition que :

  • * lorsque A représente avec les atomes de carbone et d'azote auquel il est attaché un cycle 1,3-thiazolidine,
    R₁ représente un groupement alkyle (C₁-C₆) linéaire ou ramifié substitué au moins par l'un quelconque des groupements suivants :
    • cycloalkyle (C₃-C₇),
    • phénylcycloalkyle (C₃-C₇),
    • trifluorométhyle,
    • (trifluorométhylphényl) méthyle,
    • dicycloalkyl (C₃-C₇) méthylthio,
      Figure imgb0013
      Figure imgb0014
    ou bien R₁ représente un groupement phénylcycloalkyle (C₃-C₇) ou
    Figure imgb0015
  • * lorsque B représente avec l'atome d'azote auquel il est attaché un cycle pyrrolidine,
    R₁ représente l'un quelconque des groupements suivants :
    • terbutoxy,
    • phénylcyclopropyl,
    • alkyle (C₁-C₆) linéaire ou ramifié ou alkényle (C₁-C₆) linéaire ou ramifié,
      chacun des groupements alkyle ou alkényle étant toujours substitué par au moins un groupement dicycloalkyl (C₃-C₇) méthyle, dicycloalkyl (C₃-C₇) méthylthio,
      Figure imgb0016
       ou par deux groupements cycloalkyle (C₃-C₇),
    • trifluorométhylalkyle (C₁-C₆) linéaire ou ramifié, trifluorométhylalkényle (C₁-C₆) linéaire ou ramifié éventuellement substitués par un ou plusieurs groupements phényle ou cycloalkyle (C₃-C₇),
  • * lorsque A représente avec les atomes de carbone et d'azote auquel il est attaché un cycle 2,3-dihydroindole et B représente avec l'atome d'azote auquel il est attaché un cycle pyrrolidine, alors R₁ est différent d'un groupement 3-phénylpropyl,

leurs énantiomères, diastéréoisomères et épimères ainsi que leurs sels d'addition à un acide pharmaceutiquement acceptable. provided that :
  • * when A represents with the carbon and nitrogen atoms to which it is attached a 1,3-thiazolidine ring,
    R₁ represents a linear or branched (C₁-C₆) alkyl group substituted at least by any of the following groups:
    • cycloalkyl (C₃-C₇),
    • phenylcycloalkyl (C₃-C₇),
    • trifluoromethyl,
    • (trifluoromethylphenyl) methyl,
    • dicycloalkyl (C₃-C₇) methylthio,
      Figure imgb0013
      Figure imgb0014
    or else R₁ represents a phenylcycloalkyl group (C₃-C₇) or
    Figure imgb0015
  • * when B represents with the nitrogen atom to which it is attached a pyrrolidine ring,
    R₁ represents any one of the following groups:
    • terbutoxy,
    • phenylcyclopropyl,
    • linear or branched (C₁-C₆) alkyl or linear or branched (C₁-C₆) alkenyl,
      each of the alkyl or alkenyl groups always being substituted by at least one dicycloalkyl (C₃-C₇) methyl, dicycloalkyl (C₃-C₇) methylthio group,
      Figure imgb0016
       or by two cycloalkyl groups (C₃-C₇),
    • linear or branched trifluoromethylalkyl (C₁-C₆), linear or branched trifluoromethylalkenyl (C₁-C₆) optionally substituted by one or more phenyl or cycloalkyl (C₃-C₇) groups,
  • * when A represents with the carbon and nitrogen atoms to which it is attached a 2,3-dihydroindole ring and B represents with the nitrogen atom to which it is attached a pyrrolidine ring, then R₁ is different from a group 3-phenylpropyl,

their enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid.

Parmi les acides pharmaceutiquement acceptables, on peut citer à titre non limitatif les acides chlorhydrique, sulfurique, tartrique, maléique, fumarique, méthane sulfonique, camphorique, etc...Among the pharmaceutically acceptable acids, non-limiting mention may be made of hydrochloric, sulfuric, tartaric, maleic, fumaric, methane sulphonic, camphoric acids, etc.

L'invention s'étend également au procédé de préparation des composés de formule (I) caractérisé en ce que l'on fait réagir un acide de formule (II), dont on a éventuellement séparé les isomères par une technique classique de séparation :

Figure imgb0017

dans laquelle A a la même signification que dans la formule (I) et R′₁ représente un groupement alkoxy (C₁-C₆) linéaire ou ramifié ou benzyloxy,
   sur une amine de formule (III), dont on a éventuellement séparé les isomères par une technique classique de séparation, selon une technique de couplage peptidique comme celle décrite par W. KONIG et R. GEIGER (Ber, 103, 788, 1970) :
Figure imgb0018
dans laquelle B a la même signification que dans la formule (I),
   pour conduire au composé de formule (I/a), cas particulier des composés de formule (I) :
Figure imgb0019
dans laquelle A, B et R′₁ ont la même signification que précédemment,
   que l'on déprotège, si on le souhaite, par une technique classique de déprotection,
pour conduire à l'amine de formule (IV) :
Figure imgb0020
dans laquelle A et B ont la même signification que dans la formule (I),
   que l'on fait réagir avec un acide de formule (V) en présence d'un agent de couplage classique de la synthèse peptidique :

        HO₂C-R˝₁   (V)


dans laquelle :
   R˝₁ a la même signification que R₁ à l'exception du cas où R₁ représente R′₁
   pour conduire au composé de formule (I/b), cas particulier des composés de formule (I) :
Figure imgb0021
dans laquelle A, B et R˝₁ ont la même signification que précédemment,
dérivés de formule (I/a) et (I/b) que l'on purifie, le cas échéant, par une technique classique de purification, dont on sépare, si on le souhaite, les isomères par une technique classique de séparation et que l'on transforme, si nécessaire, en leurs sels d'addition à un acide pharmaceutiquement acceptable.The invention also extends to the process for the preparation of the compounds of formula (I) characterized in that an acid of formula (II) is reacted, from which the isomers have optionally been separated by a conventional separation technique:
Figure imgb0017
in which A has the same meaning as in formula (I) and R′₁ represents a linear or branched (C₁-C₆) alkoxy or benzyloxy group,
on an amine of formula (III), the isomers of which are optionally separated by a conventional separation technique, according to a peptide coupling technique such as that described by W. KONIG and R. GEIGER (Ber, 103 , 788, 1970):
Figure imgb0018
in which B has the same meaning as in formula (I),
to lead to the compound of formula (I / a), special case of the compounds of formula (I):
Figure imgb0019
in which A, B and R′₁ have the same meaning as above,
that we deprotect, if desired, by a conventional deprotection technique,
to lead to the amine of formula (IV):
Figure imgb0020
in which A and B have the same meaning as in formula (I),
which is reacted with an acid of formula (V) in the presence of a conventional coupling agent for peptide synthesis:

HO₂C-R˝₁ (V)


in which :
R˝₁ has the same meaning as R₁ except for the case where R₁ represents R′₁
to lead to the compound of formula (I / b), special case of the compounds of formula (I):
Figure imgb0021
in which A, B and R˝₁ have the same meaning as before,
derivatives of formula (I / a) and (I / b) which are purified, if necessary, by a conventional purification technique, from which the isomers are separated, if desired, by a conventional separation technique and that it is converted, if necessary, into their addition salts with a pharmaceutically acceptable acid.

Les composés de l'invention possèdent des propriétés pharmacologiques très intéressantes. Ils inhibent fortement l'activité de la prolyl-endopeptidase ce qui les rend utiles pour le traitement des désordres mnésiques et cognitifs et des troubles neurocomportementaux associés au vieillissement et aux maladies dégénératives du système nerveux, aigües ou chroniques comme la maladie d'Alzheimer, de Pick, de Korsakoff, l'accident vasculaire cérébral, le traumatisme spinal ou la sclérose amyotrophique latérale. Ils sont de la même manière utiles dans le traitement des désordres psychiques assoicés à l'anxiété et à la dépression.The compounds of the invention have very advantageous pharmacological properties. They strongly inhibit prolyl-endopeptidase activity which makes them useful for the treatment of memory and cognitive disorders and neurobehavioral disorders associated with aging and degenerative diseases of the system. nervous, acute or chronic such as Alzheimer's, Pick's, Korsakoff's disease, stroke, spinal trauma or amyotrophic lateral sclerosis. They are similarly useful in the treatment of mental disorders associated with anxiety and depression.

La présente invention a également pour objet les compositions pharmaceutiques renfermant comme principe actif au moins un composé de formule générale (I) ou un de ses sels d'addition à un acide pharmacologiquement acceptable, seul ou en combinaison avec un ou plusieurs excipients ou véhicules inertes, non toxiques.The present invention also relates to pharmaceutical compositions containing as active principle at least one compound of general formula (I) or one of its addition salts with a pharmacologically acceptable acid, alone or in combination with one or more excipients or inert vehicles , non-toxic.

Parmi les compositions pharmaceutiques selon l'invention, on pourra citer plus particulièrement celles qui conviennent pour l'administration orale, parentérale, nasale, les comprimés simples ou dragéifiés, les comprimés sublinguaux, les sachets, les paquets, les gélules, les glossettes, les tablettes, les suppositoires, les crèmes, pommades, gels dermiques, etc...Among the pharmaceutical compositions according to the invention, mention may be made more particularly of those which are suitable for oral, parenteral, nasal administration, simple or coated tablets, sublingual tablets, sachets, packages, capsules, glossettes, tablets, suppositories, creams, ointments, dermal gels, etc.

La posologie varie selon l'âge et le poids du patient, la nature et la sévérité de l'affection ainsi que la voie d'administration.The dosage varies according to the age and weight of the patient, the nature and severity of the condition and the route of administration.

Celle-ci peut être orale, nasale, rectale ou parentérale. D'une manière générale, la posologie unitaire s'échelonne entre 0,5 et 100 mg pour un traitement en 1 à 3 prises par 24 heures.This can be oral, nasal, rectal or parenteral. In general, the unit dosage ranges from 0.5 to 100 mg for a treatment in 1 to 3 doses per 24 hours.

Les exemples suivants illustrent l'invention et ne la limitent en aucune façon.The following examples illustrate the invention and do not limit it in any way.

Les préparations A à N ne conduisent pas aux composés de l'invention mais à des produits de départ utiles dans la préparation des dérivés de formule (I).The preparations A to N do not lead to the compounds of the invention but to starting materials useful in the preparation of the derivatives of formula (I).

PREPARATION APREPARATION A :: Acide 3,3-dicyclopropylpropanoïque3,3-dicyclopropylpropanoic acid STADE A : 3,3-Dicyclopropylpropionitrile STAGE A : 3,3-Dicyclopropylpropionitrile

A 40 g de cyanure de sodium dans 45 ml de diméthylsulfoxide (DMSO), sous agitation et à 95°C, sont additionnés lentement 209 g de tosylate de 2,2-dicyclopropyléthanol (préparé à partir de 2,2-dicyclopropyléthanol et de chlorure de paratoluènesulfonyl) en solution dans 45 ml de DMSO. Le chauffage est maintenu une heure. Après filtration du précipité et lavage par de l'éther éthylique, les filtrats sont regroupés, lavés par une solution saturée de chlorure de sodium, séchés et évaporés. Le produit attendu est obtenu après distillation sous vide.
   Rendement : 90 %
   Point d'ébullition : 95-100°C (15 mm/Hg)
   Indice de réfraction : nD 22,5 = 1,457To 40 g of sodium cyanide in 45 ml of dimethylsulfoxide (DMSO), with stirring and at 95 ° C., are slowly added 209 g of 2,2-dicyclopropylethanol tosylate (prepared from 2,2-dicyclopropylethanol and of paratoluenesulfonyl chloride) dissolved in 45 ml of DMSO. Heating is maintained for one hour. After filtration of the precipitate and washing with ethyl ether, the filtrates are combined, washed with a saturated solution of sodium chloride, dried and evaporated. The expected product is obtained after vacuum distillation.
Efficiency : 90%
Boiling point : 95-100 ° C (15 mm / Hg)
Refractive index : n D 22.5 = 1.457

STADE B : Acide 3,3-dicyclopropylpropanoïque STAGE B : 3,3-Dicyclopropylpropanoic acid

45 g de potasse sont dissous dans 65 ml d'eau. 100 ml de diéthylèneglycol sont ajoutés à la solution précédente puis 30 g du produit obtenu au stade A. L'ensemble est porté à reflux jusqu'à la fin du dégagement d'ammoniac. Après refroidissement 700 ml d'eau sont ajoutés et le mélange est acidifié par de l'acide chlorhydrique 12N. Après extraction à l'éther, les phases éthérées sont regroupées, lavées à l'eau jusqu'à neutralité, séchées et évaporées. Le produit attendu est obtenu après distillation.
   Rendement : 83 %
   Point d'ébullition : 138-142°C (13 mm/Hg)
   Indice de réfraction : nD²⁷ = 1,45845 g of potassium hydroxide are dissolved in 65 ml of water. 100 ml of diethylene glycol are added to the preceding solution and then 30 g of the product obtained in stage A. The whole is brought to reflux until the end of the evolution of ammonia. After cooling 700 ml of water are added and the mixture is acidified with 12N hydrochloric acid. After extraction with ether, the ethereal phases are combined, washed with water until neutral, dried and evaporated. The expected product is obtained after distillation.
Efficiency : 83%
Boiling point : 138-142 ° C (13 mm / Hg)
Refractive index : n D ²⁷ = 1.458

PREPARATION BPREPARATION B :: Acide 4,4-dicyclopropylbutanoïque4,4-dicyclopropylbutanoic acid STADE A : 1-Bromo-3,3-dicyclopropylpropane STAGE A : 1-Bromo-3,3-dicyclopropylpropane

A une solution refroidie à - 30°C de 22 g de 3,3-dicyclopropylpropanol (obtenu par réduction du composé décrit dans la préparation A en présence d'hydrure de lithium aluminium) dans 85 ml d'éther anhydre, 15,5 g de tribromure de phosphore sont ajoutés lentement et l'ensemble est coulé après retour à température ambiante dans 7 ml d'eau glacée. La phase organique est alors lavée par une solution saturée de bicarbonate de sodium puis à l'eau jusqu'à neutralité et enfin séchée et évaporée. Le produit attendu est obtenu après distillation sous vide.
   Rendement : 60 %
   Point d'ébullition : 101-105°C (18 mm/Hg)To a solution cooled to -30 ° C of 22 g of 3,3-dicyclopropylpropanol (obtained by reduction of the compound described in preparation A in the presence of lithium aluminum hydride) in 85 ml of anhydrous ether, 15.5 g phosphorus tribromide are added slowly and the whole is poured after returning to room temperature in 7 ml of ice water. The organic phase is then washed with a saturated solution of bicarbonate of sodium then with water until neutral and finally dried and evaporated. The expected product is obtained after vacuum distillation.
Yield : 60%
Boiling point : 101-105 ° C (18 mm / Hg)

STADE B : 4,4-Dicyclopropylbutyronitrile STAGE B : 4,4-Dicyclopropylbutyronitrile

Le produit attendu est obtenu en faisant réagir le cyanure de potassium sur le composé décrit au stade précédent en milieu éthanol/eau.
   Rendement : 73 %
   Point d'ébullition : 114-117°C (17 mm/Hg)The expected product is obtained by reacting potassium cyanide on the compound described in the previous stage in ethanol / water medium.
Yield : 73%
Boiling point : 114-117 ° C (17 mm / Hg)

STADE C : Acide 4,4-dicyclopropylbutanoïque STAGE C : 4,4-Dicyclopropylbutanoic acid

Le produit attendu est obtenu en procédant comme au stade B de la préparation A avec le composé décrit au stade précédent.
   Rendement : 74 %
   Point d'ébullition : 170-172°C (16 mm/Hg)The expected product is obtained by proceeding as in stage B of preparation A with the compound described in the preceding stage.
Yield : 74%
Boiling point : 170-172 ° C (16 mm / Hg)

PREPARATION C : Acide 5,5-dicyclopropylpentanoïque PREPARATION C : 5,5-Dicyclopropylpentanoic acid

Le produit attendu est obtenu en utilisant le mode opératoire décrit dans Org. Synthese Coll. vol. II, 474 à partir du 1-bromo-3,3-dicyclopropylpropane décrit au stade A de la préparation B.
   Rendement : 74 %
   Point d'ébullition : 170-172°C (16 mm/Hg)The expected product is obtained using the procedure described in Org. Synthesis Coll. flight. II, 474 starting from 1-bromo-3,3-dicyclopropylpropane described in stage A of preparation B.
Yield : 74%
Boiling point : 170-172 ° C (16 mm / Hg)

PREPARATION D : Acide 6,6-dicyclopropylhexanoïque PREPARATION D : 6,6-Dicyclopropylhexanoic acid

Le produit attendu est obtenu en utilisant le procédé décrit dans la préparation B.The expected product is obtained using the process described in Preparation B.

PREPARATION E : Acide 5,5-dicyclopropylpropen-4-oïque PREPARATION E : 5,5-Dicyclopropylpropen-4-oic acid

20 mmoles d'iodure de (carboxypropyl)triphénylphosphonium sont placées dans 100 ml de tétrahydrofurane anhydre. 40 ml d'une solution 1M de terbutylate de potassium dans le THF sont ajoutés goutte à goutte au mélange précédent sous atmosphère d'azote.20 mmol of (carboxypropyl) triphenylphosphonium iodide are placed in 100 ml of anhydrous tetrahydrofuran. 40 ml of a 1M solution of potassium terbutylate in THF are added dropwise to the above mixture under a nitrogen atmosphere.

L'agitation est maintenue 30 minutes et une solution contenant 20 mmoles de dicyclopropylcétone dans 20 ml de THF anhydre est additionnée. L'ensemble est laissé 4 jours sous agitation à température ambiante. Après reprise par de l'eau, filtration de l'oxyde de triphénylphosphine, lavage par du dichlorométhane, la phase aqueuse est acidifiée par HCl6N et extraite au dichlorométhane. Les phases organiques sont lavées à l'eau, séchées et évaporées. Le produit attendu est obtenu après purification par chromatographie sur gel de silice en utilisant comme éluant un mélange dichlorométhane/éthanol (97/3).
   Rendement : 50 %
   Infrarouge (film liquide) νCO = 1743 et 1711 cm⁻¹Stirring is continued for 30 minutes and a solution containing 20 mmol of dicyclopropylketone in 20 ml of anhydrous THF is added. The whole is left 4 days with stirring at room temperature. After taking up in water, filtration of the triphenylphosphine oxide, washing with dichloromethane, the aqueous phase is acidified with HCl6N and extracted with dichloromethane. The organic phases are washed with water, dried and evaporated. The expected product is obtained after purification by chromatography on silica gel using a dichloromethane / ethanol mixture (97/3) as eluent.
Yield : 50%
Infrared (liquid film) ν CO = 1743 and 1711 cm⁻¹

PREPARATION F : Acide 6,6-dicyclopropylhexen-5-oïque PREPARATION F : 6,6-Dicyclopropylhexen-5-oic acid

Le produit attendu est obtenu en procédant comme dans la préparation E à partir de bromure de (carboxybutyl)triphénylphosphonium.
   Rendement : 55 %
   Infrarouge (film liquide) νCO= 1709 cm⁻¹The expected product is obtained by proceeding as in preparation E from (carboxybutyl) triphenylphosphonium bromide.
Efficiency : 55%
Infrared (liquid film) ν CO = 1709 cm⁻¹

PREPARATION G : Acide 6,6-dicyclopropylhexen-4-oïque PREPARATION G : 6,6-Dicyclopropylhexen-4-oic acid

Le produit attendu est obtenu en procédant comme dans la préparation E à partir de 2,2-dicyclopropylacétaldéhyde.
   Rendement : 54 %
   Infrarouge (nujol) νCO = 1712 cm⁻¹The expected product is obtained by proceeding as in preparation E from 2,2-dicyclopropylacetaldehyde.
Yield : 54%
Infrared (nujol) ν CO = 1712 cm⁻¹

PREPARATION H : Acide 3-trifluorométhylcinnamique PREPARATION H : 3-Trifluoromethylcinnamic acid STADE A : 3-Trifluorométhylcinnamate d'éthyle STAGE A : Ethyl 3-trifluoromethylcinnamate

450 mmoles d'hydrure de sodium sont placées dans 50 ml de diglyme anhydre. A ce mélange est ajouté, à température ambiante, une solution de 84 g de triéthylphosphonoacétate dans 300 ml de diglyme. L'agitation est maintenue jusqu'à la fin du dégazement d'hydrogène puis on ajoute une solution contenant 52 g de trifluoroacétophénone dans 100 ml de diglyme. Après 18 heures de reflux, l'ensemble est refroidi à 10°C et versé dans 500 ml d'eau. Après extraction à l'éther éthylique, séchage et évaporation, le produit attendu est purifié par distillation.
   Rendement : 67 %
   Point d'ébullition : 104-108°C (18 mm/Hg)450 mmol of sodium hydride are placed in 50 ml of anhydrous diglyme. To this mixture is added, at room temperature, a solution of 84 g of triethylphosphonoacetate in 300 ml of diglyme. Stirring is maintained until the end of the degassing of hydrogen and then a solution containing 52 g of trifluoroacetophenone in 100 ml of diglyme is added. After 18 hours of reflux, the whole is cooled to 10 ° C. and poured into 500 ml of water. After extraction with ethyl ether, drying and evaporation, the expected product is purified by distillation.
Yield : 67%
Boiling point : 104-108 ° C (18 mm / Hg)

STADE B : Acide 3-trifluorométhylcinnamique STAGE B : 3-Trifluoromethylcinnamic acid

Le produit attendu est obtenu par saponification du composé décrit au stade précédent.
   Rendement : 92 %
   Point de fusion : 95°CThe expected product is obtained by saponification of the compound described in the previous stage.
Yield : 92%
Melting point : 95 ° C

PREPARATION I : Acide 3-phényl-3-trifluorométhylpropanoïque PREPARATION I : 3-Phenyl-3-trifluoromethylpropanoic acid

Le produit attendu est obtenu par hydrogénation catalytique en milieu éthanolique du composé décrit au stade A de la préparation A en utilisant le charbon palladié comme catalyseur puis saponification.
   Rendement : 90 %
   Point de fusion : 72°CThe expected product is obtained by catalytic hydrogenation in an ethanolic medium of the compound described in stage A of preparation A using palladium on carbon as catalyst then saponification.
Efficiency : 90%
Melting point : 72 ° C

PREPARATION J : Acide 4-phényl-4-trifluorométhylbutanoïque PREPARATION J : 4-Phenyl-4-trifluoromethylbutanoic acid

Le produit attendu est obtenu en procédant comme dans la préparation B à partir de 3-phényl-3-trifluorométhylpropanol (lui-même obtenu par réduction du 3-phényl-3-trifluorométhylpropanoate d'éthyle).
   Infrarouge (nujol) νCO = 1728 cm⁻¹The expected product is obtained by proceeding as in preparation B from 3-phenyl-3-trifluoromethylpropanol (itself obtained by reduction of ethyl 3-phenyl-3-trifluoromethylpropanoate).
Infrared (nujol) ν CO = 1728 cm⁻¹

PREPARATION K : Acide 5-phényl-5-trifluorométhylpentanoïque PREPARATION K : 5-Phenyl-5-trifluoromethylpentanoic acid

Le produit attendu est obtenu en procédant comme dans la préparation B à partir du 4-phényl-4-trifluorométhylbutanol (lui-même obtenu par réduction du composé obtenu dans la préparation J).
   Point d'ébullition : 106-110°C (16 mm/Hg)The expected product is obtained by proceeding as in preparation B from 4-phenyl-4-trifluoromethylbutanol (itself obtained by reduction of the compound obtained in preparation J).
Boiling point : 106-110 ° C (16 mm / Hg)

PREPARATION L : Acide 5-cyclopentyl-5-trifluorométhylpentanoïque PREPARATION L : 5-Cyclopentyl-5-trifluoromethylpentanoic acid

Le produit attendu est obtenu en procédant comme dans la préparation B à partir du 4-cyclopentyl-4-trifluorométhylbutanol.The expected product is obtained by proceeding as in preparation B from 4-cyclopentyl-4-trifluoromethylbutanol.

PREPARATION M : Acide 3-(dicyclopropylméthylthio)propanoïque PREPARATION M : 3- (Dicyclopropylmethylthio) propanoic acid STADE A : 3-(dicyclopropylméthylthio)propionate de méthyle STAGE A : methyl 3- (dicyclopropylmethylthio) propionate

Une solution contenant 6,8 g de dicyclopropylmercaptan (obtenu par réduction par le borohydrure de sodium de la dicyclopropylthiocétone elle-même préparée par action du réactif de LAWESSON sur la dicyclopropylcétone) dans 10 ml d'éthanol est ajoutée à une solution d'éthylate de sodium. Après 10 minutes d'agitation, on ajoute au mélange précédant 10 g de 3-bromopropionate de méthyle dans 10 ml d'éthanol. L'ensemble est maintenu 18 heures sous agitation à température ambiante. Le produit attendu est obtenu après filtration du bromure de sodium, évaporation et distillation.
   Rendement : 66 %
   Point d'ébullition : 158-160°C (16 mm/Hg)A solution containing 6.8 g of dicyclopropylmercaptan (obtained by reduction with sodium borohydride of dicyclopropylthioketone itself prepared by the action of the LAWESSON reagent on dicyclopropyl ketone) in 10 ml of ethanol is added to a solution of ethyl ethoxide. sodium. After 10 minutes of stirring, 10 g of methyl 3-bromopropionate in 10 ml of ethanol are added to the preceding mixture. The whole is kept for 18 hours with stirring at room temperature. The expected product is obtained after filtration of the sodium bromide, evaporation and distillation.
Yield : 66%
Boiling point : 158-160 ° C (16 mm / Hg)

STADE B : Acide 3-(dicyclopropylméthylthio)propanoïque STAGE B : 3- (Dicyclopropylmethylthio) propanoic acid

Le produit attendu est obtenu par saponification du composé décrit au stade précédent.
   Rendement : 84 %
   Infrarouge (film liquide) νCO = 1711 cm⁻¹The expected product is obtained by saponification of the compound described in the previous stage.
Efficiency : 84%
Infrared (liquid film) ν CO = 1711 cm⁻¹

PREPARATION N : Acide 3-dicyclopropylméthylaminocarbonylpropanoïque PREPARATION N : 3-Dicyclopropylmethylaminocarbonylpropanoic acid

Le produit attendu est obtenu par couplage peptidique de la dicyclopropylméthylamine avec le monosuccinate de méthyle selon la technique décrite par W. KONIG et R. GEIGER (Ber, 103, 788, 1970) puis saponification.
   Infrarouge (nujol) :
      νCO (acide) = 1703 cm⁻¹
      νCO (amide) = 1631 cm⁻¹The expected product is obtained by peptide coupling of dicyclopropylmethylamine with methyl monosuccinate according to the technique described by W. KONIG and R. GEIGER (Ber, 103, 788, 1970) then saponification.
Infrared (nujol):
ν CO (acid) = 1703 cm⁻¹
ν CO (amide) = 1631 cm⁻¹

EXEMPLE 1 : (3S)-2-Aza-2-tertbutyloxycarbonyl-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 1 : (3S) -2-Aza-2-tertbutyloxycarbonyl-3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2 . 2 . 2] octane

En utilisant la technique de couplage peptidique (dicyclohexylcarbodiimide/hydroxybenzotriazole-DCC/HOBT) décrite par W. KONIG et R. GEIGER (Ber. 103, 788, 1970) et le diméthylformamide comme solvant, on prépare à partir de pyrrolidine et d'acide (3S)-2-aza-2-tertbutyloxycarbonyl bicyclo[2.2.2]octane-3-carboxylique, le produit attendu qui est purifié par cristallisation dans de l'acétate d'éthyle.
   Rendement : 73 %
   Point de fusion : 150-152°C
   Pouvoir rotatoire : [α]D²⁰ = - 10,5° (c = 1 %, EtOH) Microanalyse élémentaire : C % H % N % calculé 66,20 9,15 9,08 trouvé 66,24 9,40 9,06 Using the peptide coupling technique (dicyclohexylcarbodiimide / hydroxybenzotriazole-DCC / HOBT) described by W. KONIG and R. GEIGER (Ber. 103 , 788, 1970) and dimethylformamide as solvent, it is prepared from pyrrolidine and acid (3S) -2-aza-2-tertbutyloxycarbonyl bicyclo [2.2.2] octane-3-carboxylic, the expected product which is purified by crystallization from ethyl acetate.
Yield : 73%
Melting point : 150-152 ° C
Rotatory power : [α] D ²⁰ = - 10.5 ° (c = 1%, EtOH) Elementary microanalysis : VS % H% NOT % calculated 66.20 9.15 9.08 find 66.24 9.40 9.06

EXEMPLE 2 : (3R)-2-Aza-2-tertbutyloxycarbonyl-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 2 : (3R) -2-Aza-2-tertbutyloxycarbonyl-3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane

Le produit attendu est obtenu selon le même procédé que celui décrit dans l'exemple 1 mais en utilisant l'isomère (3R) de l'acide 2-aza-2-tertbutyloxycarbonyl bicyclo[2.2.2]octane-3-carboxylique à la place de l'isomère (3S).
   Point de fusion : 150-152°C Microanalyse élémentaire : C % H % N % calculé 66,20 9,15 9,08 trouvé 66,93 9,15 9,18 The expected product is obtained according to the same process as that described in Example 1 but using the (3R) isomer of 2-aza-2-tertbutyloxycarbonyl bicyclo [2.2.2] octane-3-carboxylic acid with the place of the isomer (3S).
Melting point : 150-152 ° C Elementary microanalysis : VS % H% NOT % calculated 66.20 9.15 9.08 find 66.93 9.15 9.18

Les exemples 3 à 6 ont été obtenus selon le procédé décrit dans l'exemple 1 en utilisant les produits de départ connus correspondants.Examples 3 to 6 were obtained according to the process described in Example 1 using the corresponding known starting materials.

EXEMPLE 3 : (1S, 3S, 4R)-2-Aza-2-tertbutyloxycarbonyl-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.1]heptane EXAMPLE 3 : (1S, 3S, 4R) -2-Aza-2-tertbutyloxycarbonyl-3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2 . 2 . 1] heptane

   Point de fusion : 142-144°C Melting point : 142-144 ° C

EXEMPLE 4 : (3S)-2-Aza-2-tertbutyloxycarbonyl-3-[(3-azabicyclo[3.3.0]octan-3-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 4 : (3S) -2-Aza-2-tertbutyloxycarbonyl-3 - [(3-azabicyclo [3.3.0] octan-3-yl) carbonyl] bicyclo [2.2.2] octane

   Point de fusion : 154-156°C Microanalyse élémentaire : C % H % N % calculé 68,93 9,26 8,04 trouvé 68,99 9,25 8,04 Melting point : 154-156 ° C Elementary microanalysis : VS % H% NOT % calculated 68.93 9.26 8.04 find 68.99 9.25 8.04

EXEMPLE 5 : (2S, 3aS, 7aS)-1-(4-Phénylbutyryl)-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole EXAMPLE 5 : (2S, 3aS, 7aS) -1- (4-Phenylbutyryl) -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 67,0567.05 9,389.38 8,698.69 trouvéfind 66,6066.60 9,529.52 8,708.70

EXEMPLE 6 : (1R, 3S, 4R)-2-Aza-2-tertbutyloxycarbonyl-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.1]heptane EXAMPLE 6 : (1R, 3S, 4R) -2-Aza-2-tertbutyloxycarbonyl-3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.1] heptane

   Point de fusion : 112°C Microanalyse élémentaire : C % H % N % calculé 65,28 8,90 9,52 trouvé 65,28 8,82 9,68 Melting point : 112 ° C Elementary microanalysis : VS % H% NOT % calculated 65.28 8.90 9.52 find 65.28 8.82 9.68

EXEMPLE 7 : (3S)-2-Aza-2-(4-phénylbutyryl)-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 7 : (3S) -2-Aza-2- (4-phenylbutyryl) -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2 . 2 . 2] octane STADE A : (3S)-2-Aza-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane STAGE A : (3S) -2-Aza-3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane

37 mmoles du composé décrit dans l'exemple 1 sont dissous dans 100 ml d'acétate d'éthyle anhydre. En maintenant la température à 20°C, on fait passer un courant d'acide chlorhydrique et l'agitation est maintenue 18 heures à température ambiante. Le solvant est évaporé et le résidu repris par 100 ml d'eau. L'insoluble est filtré et le filtrat, après alcalinisation par addition de bicarbonate de sodium, est amené à sec. Le résidu est enfin repris successivement par 100 ml d'éthanol, 100 ml de dichlorométhane puis 100 ml d'éther éthylique. Le produit attendu est obtenu après filtration des sels et évaporation.
   Rendement : 89 %
   Point de fusion : 117°C37 mmol of the compound described in Example 1 are dissolved in 100 ml of anhydrous ethyl acetate. Maintaining the temperature at 20 ° C, a stream of hydrochloric acid is passed and stirring is continued for 18 hours at room temperature. The solvent is evaporated and the residue taken up in 100 ml of water. The insoluble material is filtered and the filtrate, after alkalization by addition of sodium bicarbonate, is brought to dryness. The residue is finally taken up successively with 100 ml of ethanol, 100 ml of dichloromethane and then 100 ml of ethyl ether. The expected product is obtained after filtration of the salts and evaporation.
Efficiency : 89%
Melting point : 117 ° C

STADE B : (3S)-2-Aza-2-(4-phénylbutyryl)-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane STAGE B : (3S) -2-Aza-2- (4-phenylbutyryl) -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane

Le produit attendu est obtenu selon le même procédé que celui décrit dans l'exemple 1 mais en utilisant l'acide 4-phénylbutyrique et le produit obtenu au stade A. Il est purifié par chromatographie sur silice en utilisant comme solvant d'élution un mélange dichlorométhane/méthanol (95/5) et cristallisé dans un mélange acétone-oxyde d'isopropyle.
   Point de fusion : 77°C Microanalyse élémentaire : C % H % N % calculé 74,54 8,53 7,90 trouvé 74,71 8,56 7,93 The expected product is obtained according to the same process as that described in Example 1 but using 4-phenylbutyric acid and the product obtained in Stage A. It is purified by chromatography on silica using a mixture of elution solvents dichloromethane / methanol (95/5) and crystallized from an acetone-isopropyl oxide mixture.
Melting point : 77 ° C Elementary microanalysis : VS % H% NOT % calculated 74.54 8.53 7.90 find 74.71 8.56 7.93

Les exemples 8 à 34 ont été obtenus selon le procédé décrit dans l'exemple 7 en utilisant les produits de départ correspondants connus ou décrits dans les préparations A à N.Examples 8 to 34 were obtained according to the process described in Example 7 using the corresponding starting materials known or described in preparations A to N.

EXEMPLE 8 : (3R)-2-Aza-2-(4-phénylbutyryl)-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 8 : (3R) -2-Aza-2- (4-phenylbutyryl) -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2 . 2 . 2] octane

   Point de fusion : 70°C Melting point : 70 ° C

EXEMPLE 9 : (1S, 3S, 4R)-2-Aza-2-(4-phénylbutyryl)-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.1]heptane EXAMPLE 9 : (1S, 3S, 4R) -2-Aza-2- (4-phenylbutyryl) -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.1] heptane

   Infrarouge (nujol) : νCO (amide) = 1650 cm⁻¹ Infrared (nujol): ν CO (amide) = 1650 cm⁻¹

EXEMPLE 10 : (2S, 3aS, 7aS)-1-Tertbutyloxycarbonyl-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole EXAMPLE 10 : (2S, 3aS, 7aS) -1-Tertbutyloxycarbonyl-2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 74,9674.96 8,758.75 7,607.60 trouvéfind 74,5774.57 9,169.16 7,167.16

EXEMPLE 11 : (3S)-2-(4-Phénylbutyryl)-3-[(pyrrolidin-1-yl)carbonyl]-1,2,3,4-tétrahydroisoquinoléine EXAMPLE 11 : (3S) -2- (4-Phenylbutyryl) -3 - [(pyrrolidin-1-yl) carbonyl] -1,2,3,4-tetrahydroisoquinoline

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 76,5676.56 7,507.50 7,447.44 trouvéfind 76,0776.07 6,996.99 7,207.20

EXEMPLE 12 : (3S)-2-Aza-2-[5,5-(dicyclopropyl)pentanoyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 12 : (3S) -2-Aza-2- [5,5- (dicyclopropyl) pentanoyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 74,1574.15 9,749.74 7,527.52 trouvéfind 74,2274.22 10,1510.15 7,627.62

EXEMPLE 13 : (3S)-2-Aza-2-[6,6-(dicyclopropyl)hexanoyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 13 : (3S) -2-Aza-2- [6,6- (dicyclopropyl) hexanoyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane

   Point de fusion : 86°C Melting point : 86 ° C

EXEMPLE 14 : (2S, 3aS, 7aS)-1-[5,5-(dicyclopropyl)pentanoyl]-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole EXAMPLE 14 : (2S, 3aS, 7aS) -1- [5,5- (dicyclopropyl) pentanoyl] -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 74,5774.57 9,919.91 7,257.25 trouvéfind 74,0474.04 9,999.99 7,297.29

EXEMPLE 15 : (2S, 3aS, 7aS)-1-[3,3-(dicyclopropyl)propionyl]-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole EXAMPLE 15 : (2S, 3aS, 7aS) -1- [3,3- (dicyclopropyl) propionyl] -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole

   Point de fusion : 110-112°C Microanalyse élémentaire : C % H % N % calculé 73,70 9,56 7,81 trouvé 73,36 9,61 8,14 Melting point : 110-112 ° C Elementary microanalysis : VS % H% NOT % calculated 73.70 9.56 7.81 find 73.36 9.61 8.14

EXEMPLE 16 : (2S, 3aS, 7aS)-1-[4,4-(Dicyclopropyl)butyryl]-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole EXAMPLE 16 : (2S, 3aS, 7aS) -1- [4,4- (Dicyclopropyl) butyryl] -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 74,1574.15 9,749.74 7,527.52 trouvéfind 73,8173.81 9,649.64 7,687.68

EXEMPLE 17 : (1S, 3S, 4R)-2-Aza-2-[5,5-(dicyclopropyl)pentanoyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.1]heptane EXAMPLE 17 : (1S, 3S, 4R) -2-Aza-2- [5,5- (dicyclopropyl) pentanoyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2 . 1] heptane

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 73,7073.70 9,569.56 7,817.81 trouvéfind 73,9373.93 9,559.55 7,827.82

EXEMPLE 18 : (3S)-2-Aza-2-[6,6-(dicyclopropyl)hexèn-5-oyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 18 : (3S) -2-Aza-2- [6,6- (dicyclopropyl) hexen-5-oyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane

   Infrarouge (nujol) :
      νCO (amide) = 1676 et 1653 cm⁻¹
      νC=C = 1630 cm⁻¹ Infrared (nujol):
ν CO (amide) = 1676 and 1653 cm⁻¹
ν C = C = 1630 cm⁻¹

EXEMPLE 19 : (3S)-2-Aza-2-[(E)-cinnamoyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 19 : (3S) -2-Aza-2 - [(E) -cinnamoyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane

   Point de fusion : 184°C Melting point : 184 ° C

EXEMPLE 20 : (3S)-2-Aza-2-[(E)-4-phénylbutèn-3-oyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 20 : (3S) -2-Aza-2 - [(E) -4-phenylbuten-3-oyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane

   Point de fusion : 100-105°C Melting point : 100-105 ° C

EXEMPLE 21 : (3S)-2-Aza-2-[5,5-(dicyclopropyl)pentèn-4-oyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 21 : (3S) -2-Aza-2- [5,5- (dicyclopropyl) penten-4-oyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane


   Infrarouge (nujol) : νCO (amide) = 1656 et 1637 cm⁻¹
Infrared (nujol): ν CO (amide) = 1656 and 1637 cm⁻¹

EXEMPLE 22 : (2S, 3aS, 7aS)-1-(3-Trifluorométhylcinnamoyl)-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole EXAMPLE 22 : (2S, 3aS, 7aS) -1- (3-Trifluoromethylcinnamoyl) -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole

   Point de fusion : 148°C Microanalyse élémentaire : C % H % N % calculé 65,70 6,47 6,66 trouvé 65,66 6,64 6,75 Melting point : 148 ° C Elementary microanalysis : VS % H% NOT % calculated 65.70 6.47 6.66 find 65.66 6.64 6.75

EXEMPLE 23 : (2S, 3aS, 7aS)-1-(3-Trifluorométhyl-3-phénylpropanoyl)-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole, isomère α EXAMPLE 23 : (2S, 3aS, 7aS) -1- (3-Trifluoromethyl-3-phenylpropanoyl) -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole, isomer α

   Point de fusion : 134°C Microanalyse élémentaire : C % H % N % calculé 65,38 6,91 6,63 trouvé 65,46 6,93 6,66 Melting point : 134 ° C Elementary microanalysis : VS % H% NOT % calculated 65.38 6.91 6.63 find 65.46 6.93 6.66

EXEMPLE 24 : (2S, 3aS, 7aS)-1-(3-Trifluorométhyl-3-phénylpropanoyl)-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole, isomère β EXAMPLE 24 : (2S, 3aS, 7aS) -1- (3-Trifluoromethyl-3-phenylpropanoyl) -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole, β isomer

   Point de fusion : 98°C Microanalyse élémentaire : C % H % N % calculé 65,38 6,91 6,63 trouvé 65,42 6,99 6,51 Melting point : 98 ° C Elementary microanalysis : VS % H% NOT % calculated 65.38 6.91 6.63 find 65.42 6.99 6.51

EXEMPLE 25 : (2S, 3aS, 7aS)-1-[(R,S)-4-Trifluorométhyl-4-phénylbutanoyl]-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole EXAMPLE 25 : (2S, 3aS, 7aS) -1 - [(R, S) -4-Trifluoromethyl-4-phenylbutanoyl] -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 66,0466.04 7,167.16 6,426.42 trouvéfind 65,7865.78 7,187.18 6,256.25

EXEMPLE 26 : (2S, 3aS, 7aS)-1-[(R,S)-5-Trifluorométhyl-5-phénylpentanoyl]-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole EXAMPLE 26 : (2S, 3aS, 7aS) -1 - [(R, S) -5-Trifluoromethyl-5-phenylpentanoyl] -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 66,6566.65 7,387.38 6,226.22 trouvéfind 66,9766.97 7,607.60 6,146.14

EXEMPLE 27 : (3S)-2-Aza-2-benzyloxycarbonyl-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 27 : (3S) -2-Aza-2-benzyloxycarbonyl-3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane

   Point de fusion : 105°C Microanalyse élémentaire : C % H % N % calculé 70,15 7,65 8,18 trouvé 70,04 7,50 8,17 Melting point : 105 ° C Elementary microanalysis : VS % H% NOT % calculated 70.15 7.65 8.18 find 70.04 7.50 8.17

EXEMPLE 28 : (2S, 3aS, 7aS)-1-[3-(Dicyclopropylméthylthio)propanoyl]-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole EXAMPLE 28 : (2S, 3aS, 7aS) -1- [3- (Dicyclopropylmethylthio) propanoyl] -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % S %S% calculécalculated 68,2868.28 8,978.97 6,926.92 7,927.92 trouvéfind 67,8567.85 9,189.18 7,117.11 7,767.76

EXEMPLE 29 : (3S)-2-Aza-2-[3-(N-Benzylanilinocarbonyl)propionyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 29 : (3S) -2-Aza-2- [3- (N-Benzylanilinocarbonyl) propionyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 73,5473.54 7,457.45 8,878.87 trouvéfind 72,3572.35 7,377.37 8,928.92

EXEMPLE 30 : (3S)-2-Aza-2-[3-(dicyclopropylméthylaminocarbonyl)propionyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 30 : (3S) -2-Aza-2- [3- (dicyclopropylmethylaminocarbonyl) propionyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 68,8068.80 8,798.79 10,4610.46 trouvéfind 68,9668.96 8,818.81 10,4710.47

EXEMPLE 31 : (3S)-2-Aza-2-[((1S,2S)-2-phénylcycloprop-1-yl)carbonyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 31 : (3S) -2-Aza-2 - [((1S, 2S) -2-phenylcycloprop-1-yl) carbonyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane

   Pouvoir rotatoire : [α]D 21,5 = + 163,7° (c = 1 %, éthanol) Microanalyse élémentaire : C % H % N % calculé 74,97 8,01 7,95 trouvé 75,05 8,10 7,71 Rotatory power : [α] D 21.5 = + 163.7 ° (c = 1%, ethanol) Elementary microanalysis : VS % H% NOT % calculated 74.97 8.01 7.95 find 75.05 8.10 7.71

EXEMPLE 32 : (3S)-2-Aza-2-[((1R,2R)-2-phénylcycloprop-1-yl)carbonyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 32 : (3S) -2-Aza-2 - [((1R, 2R) -2-phenylcycloprop-1-yl) carbonyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.2] octane

   Pouvoir rotatoire : [α]D 21.5 = - 148,1° (c = 1 %, éthanol) Microanalyse élémentaire : C % H % N % calculé 74,97 8,01 7,95 trouvé 74,73 8,10 7,67 Rotatory power : [α] D 21.5 = - 148.1 ° (c = 1%, ethanol) Elementary microanalysis : VS % H% NOT % calculated 74.97 8.01 7.95 find 74.73 8.10 7.67

EXEMPLE 33 : (3S)-2-Aza-2-(6,6-dicyclopropylhexen-4-oyl)-3-[(pyrrolidin-1-yl)carbonyl)bicyclo[2.2.2]octane EXAMPLE 33 : (3S) -2-Aza-2- (6,6-dicyclopropylhexen-4-oyl) -3 - [(pyrrolidin-1-yl) carbonyl) bicyclo [2.2.2] octane

   Infrarouge (film liquide) νCO (amide) = 1639 cm⁻¹ Infrared (liquid film) ν CO (amide) = 1639 cm⁻¹

EXEMPLE 34 : (2S, 3aS, 7aS)-1-(5-cyclopentyl-5-trifluorométhylpentanoyl)-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole EXAMPLE 34 : (2S, 3aS, 7aS) -1- (5-cyclopentyl-5-trifluoromethylpentanoyl) -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 65,1365.13 8,438.43 6,336.33 trouvéfind 65,0565.05 8,438.43 6,346.34

Les exemples 35 à 43 ont été obtenus selon le procédé décrit dans l'exemple 1 mais en utilisant les produits de départ correspondants.Examples 35 to 43 were obtained according to the method described in Example 1 but using the corresponding starting materials.

EXEMPLE 35 : (2S, 3aS, 7aS)-1-Tertbutyloxycarbonyl-2-[(azetidin-1-yl)carbonyl]perhydroindole EXAMPLE 35 : (2S, 3aS, 7aS) -1-Tertbutyloxycarbonyl-2 - [(azetidin-1-yl) carbonyl] perhydroindole

   Point de fusion : 130°C Microanalyse élémentaire : C % H % N % calculé 66,20 9,15 9,08 trouvé 66,13 9,21 8,94 Melting point : 130 ° C Elementary microanalysis : VS % H% NOT % calculated 66.20 9.15 9.08 find 66.13 9.21 8.94

EXEMPLE 36 : (2S, 3aS, 7aS)-1-Tertbutyloxycarbonyl-2-[(piperidin-1-yl)carbonyl]perhydroindole EXAMPLE 36 : (2S, 3aS, 7aS) -1-Tertbutyloxycarbonyl-2 - [(piperidin-1-yl) carbonyl] perhydroindole

   Point de fusion : 132°C Microanalyse élémentaire : C % H % N % calculé 67,82 9,59 8,33 trouvé 67,53 9,58 8,40 Melting point : 132 ° C Elementary microanalysis : VS % H% NOT % calculated 67.82 9.59 8.33 find 67.53 9.58 8.40

EXEMPLE 37 : (2S, 3aS, 7aS)-1-Tertbutyloxycarbonyl-2-[(homopiperidin-1-yl)carbonyl]perhydroindole EXAMPLE 37 : (2S, 3aS, 7aS) -1-Tertbutyloxycarbonyl-2 - [(homopiperidin-1-yl) carbonyl] perhydroindole

   Point de fusion : 122°C Microanalyse élémentaire : C % H % N % calculé 68,54 9,78 7,99 trouvé 68,20 9,64 7,79 Melting point : 122 ° C Elementary microanalysis : VS % H% NOT % calculated 68.54 9.78 7.99 find 68.20 9.64 7.79

EXEMPLE 38 : (2S, 3aS, 7aS)-1-Tertbutyloxycarbonyl-2-[(2-azabicyclo[2.2.2]octan-2-yl)carbonyl]perhydroindole EXAMPLE 38 : (2S, 3aS, 7aS) -1-Tertbutyloxycarbonyl-2 - [(2-azabicyclo [2.2.2] octan-2-yl) carbonyl] perhydroindole

   Point de fusion : 150-152°C Microanalyse élémentaire : C % H % N % calculé 69,58 9,45 7,73 trouvé 69,58 9,56 8,07 Melting point : 150-152 ° C Elementary microanalysis : VS % H% NOT % calculated 69.58 9.45 7.73 find 69.58 9.56 8.07

EXEMPLE 39 : (3S)-2-Aza-2-tertbutyloxycarbonyl-3-[(thiazolidin-3-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 39 : (3S) -2-Aza-2-tertbutyloxycarbonyl-3 - [(thiazolidin-3-yl) carbonyl] bicyclo [2.2.2] octane

   Point de fusion : 174°C Microanalyse élémentaire : C % H % N % S % calculé 58,87 8,03 8,58 9,82 trouvé 59,11 8,27 8,73 9,14 Melting point : 174 ° C Elementary microanalysis : VS % H% NOT % S% calculated 58.87 8.03 8.58 9.82 find 59.11 8.27 8.73 9.14

EXEMPLE 40 : (3S)-2-Aza-2-tertbutyloxycarbonyl-3-[(pyrrolin-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 40 : (3S) -2-Aza-2-tertbutyloxycarbonyl-3 - [(pyrrolin-1-yl) carbonyl] bicyclo [2.2.2] octane

   Point de fusion : 190°C Microanalyse élémentaire : C % H % N % calculé 66,64 8,55 9,14 trouvé 66,76 8,52 9,24 Melting point : 190 ° C Elementary microanalysis : VS % H% NOT % calculated 66.64 8.55 9.14 find 66.76 8.52 9.24

EXEMPLE 41 : (3S)-2-Aza-2-[5,5-(dicyclopropyl)pentanoyl]-3-[(thiazolidin-3-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 41 : (3S) -2-Aza-2- [5,5- (dicyclopropyl) pentanoyl] -3 - [(thiazolidin-3-yl) carbonyl] bicyclo [2.2.2] octane

   Point de fusion : 98-100°C
   Infrarouge (nujol) νCO (amide) = 1635 cm⁻¹ Melting point : 98-100 ° C
Infrared (nujol) ν CO (amide) = 1635 cm⁻¹

EXEMPLE 42 : (3S)-2-Aza-2-(4-phénylbutyryl)-3-[(imidazol-1-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 42 : (3S) -2-Aza-2- (4-phenylbutyryl) -3 - [(imidazol-1-yl) carbonyl] bicyclo [2.2 . 2] octane

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 71,7771.77 7,177.17 11,9611.96 trouvéfind 71,9571.95 7,227.22 12,0312.03

EXEMPLE 43 : (3S)-2-Aza-2-(4-phénylbutyryl)-2-[pyrazol-2-yl)carbonyl]bicyclo[2.2.2]octane EXAMPLE 43 : (3S) -2-Aza-2- (4-phenylbutyryl) -2- [pyrazol-2-yl) carbonyl] bicyclo [2.2.2] octane

   Infrarouge (nujol) νCO (amide) = 1637 cm⁻¹ Infrared (nujol) ν CO (amide) = 1637 cm⁻¹

EXEMPLE 44 : (2S, 3aS, 7aS)-1-(5-phényl-5-trifluorométhylpentanoyl)-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole, isomère α EXAMPLE 44 : (2S, 3aS, 7aS) -1- (5-phenyl-5-trifluoromethylpentanoyl) -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole, α isomer et EXEMPLE 45 : (2S, 3aS, 7aS)-1-(5-phényl-5-trifluorométhylpentanoyl)-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole, isomère β and EXAMPLE 45 : (2S, 3aS, 7aS) -1- (5-phenyl-5-trifluoromethylpentanoyl) -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole, β isomer

Les exemples 44 et 45 ont été préparés par séparation des isomères de l'exemple 26 par chromatographie sur gel de silice en utilisant comme éluant un mélange toluène-acétate d'éthyle 70/30. Les isomères ont été nommés α et β par ordre de sortie de colonne.Examples 44 and 45 were prepared by separation of the isomers of Example 26 by chromatography on silica gel using a 70/30 toluene-ethyl acetate mixture as eluent. The isomers were named α and β in order of leaving the column.

La pureté isomérique des deux composés a été contrôlée sur colonne chirale (Chiralpak ; longueur = 25 cm, diamètre intérieur = 4,6 mm, taille des particules = 10 µm) en utilisant comme solvant d'élution un mélange heptane/isopropanol/diéthylamine (85/15/0,05).

Exemple 44
: temps de rétention = 12,3 min
Exemple 45
: temps de rétention = 10,8 min
The isomeric purity of the two compounds was checked on a chiral column (Chiralpak; length = 25 cm, internal diameter = 4.6 mm, particle size = 10 µm) using as elution solvent a heptane / isopropanol / diethylamine mixture ( 85/15 / 0.05).
Example 44
: retention time = 12.3 min
Example 45
: retention time = 10.8 min

EXEMPLE 46 : 3-[5,5-Dicyclopropylpentanoyl]-4-[2,5-dihydropyrrol-1-yl)carbonyl]thiazolidine EXAMPLE 46 : 3- [5,5-Dicyclopropylpentanoyl] -4- [2,5-dihydropyrrol-1-yl) carbonyl] thiazolidine

L'exemple 46 a été préparé selon le procédé décrit dans l'exemple 7.Example 46 was prepared according to the method described in Example 7.

Les exemples 47 à 58 ont été synthétisés selon le procédé décrit dans l'exemple 7 en utilisant les produits de départ correspondants.Examples 47 to 58 were synthesized according to the method described in Example 7 using the corresponding starting materials.

EXEMPLE 47 : (1S,3S,4R)-2-Aza-2-[((1S,2S)-2-phénylcycloprop-1-yl)carbonyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.1]heptane EXAMPLE 47 : (1S, 3S, 4R) -2-Aza-2 - [((1S, 2S) -2-phenylcycloprop-1-yl) carbonyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [ 2.2.1] heptane

   Point de fusion : 175°C Microanalyse élémentaire : C % H % N % calculé 74,53 7,74 8,28 trouvé 74,45 7,68 8,16 Melting point : 175 ° C Elementary microanalysis : VS % H% NOT % calculated 74.53 7.74 8.28 find 74.45 7.68 8.16

EXEMPLE 48 : (1S,3S,4R)-2-Aza-2-[((1R,2R)-2-phénylcycloprop-1-yl)carbonyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.1]heptane EXAMPLE 48 : (1S, 3S, 4R) -2-Aza-2 - [((1R, 2R) -2-phenylcycloprop-1-yl) carbonyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [ 2.2.1] heptane

   Point de fusion : 153°C Microanalyse élémentaire : C % H % N % calculé 74,53 7,74 8,28 trouvé 74,44 7,92 7,95 Melting point : 153 ° C Elementary microanalysis : VS % H% NOT % calculated 74.53 7.74 8.28 find 74.44 7.92 7.95

EXEMPLE 49 : (2S,3aS,7aS)-1-[((1S,2S)-2-phénylcycloprop-1-yl)carbonyl]-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole EXAMPLE 49 : (2S, 3aS, 7aS) -1 - [((1S, 2S) -2-phenylcycloprop-1-yl) carbonyl] -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole

   Point de fusion : 142°C Microanalyse élémentaire : C % H % N % calculé 75,38 8,25 7,64 trouvé 75,37 8,27 7,65 Melting point : 142 ° C Elementary microanalysis : VS % H% NOT % calculated 75.38 8.25 7.64 find 75.37 8.27 7.65

EXEMPLE 50 : (2S,3aS,7aS)-1-[((1R,2R)-2-phénylcycloprop-1-yl)carbonyl]-2-[(pyrrolidin-1-yl)carbonyl]perhydroindole EXAMPLE 50 : (2S, 3aS, 7aS) -1 - [((1R, 2R) -2-phenylcycloprop-1-yl) carbonyl] -2 - [(pyrrolidin-1-yl) carbonyl] perhydroindole

   Point de fusion : 170°C Microanalyse élémentaire : C % H % N % calculé 75,38 8,25 7,64 trouvé 75,04 8,32 7,58 Melting point : 170 ° C Elementary microanalysis : VS % H% NOT % calculated 75.38 8.25 7.64 find 75.04 8.32 7.58

EXEMPLE 51 : (4R)-3-[((1S,2S)-2-phénylcycloprop-1-yl)carbonyl]-4-[(pyrrolidin-1-yl)carbonyl]thiazolidine EXAMPLE 51 : (4R) -3 - [((1S, 2S) -2-phenylcycloprop-1-yl) carbonyl] -4 - [(pyrrolidin-1-yl) carbonyl] thiazolidine

   Point de fusion : 134°C Melting point : 134 ° C

EXEMPLE 52 : (4R)-3-[((1R,2R)-2-phénylcycloprop-1-yl)carbonyl]-4-[(pyrrolidin-1-yl)carbonyl]thiazolidine EXAMPLE 52 : (4R) -3 - [((1R, 2R) -2-phenylcycloprop-1-yl) carbonyl] -4 - [(pyrrolidin-1-yl) carbonyl] thiazolidine

   Point de fusion : 200°C Melting point : 200 ° C

Les composés des exemples 31, 47, 49, 51, 53, 55, 57 et 32, 48, 50, 52, 54, 56, 58 peuvent également être obtenus à partir des acides 2-phénylcycloprop-1-yl carboxyliques de configuration respectives (1S,2S) et (1R,2R) préparés selon le procédé décrit dans "Optical résolution for Chemical compounds" (vol.2, part I / Optical Resolution information center, Manhattan College, Riverdale - NY 10471, USA).The compounds of Examples 31, 47, 49, 51, 53, 55, 57 and 32, 48, 50, 52, 54, 56, 58 can also be obtained from 2-phenylcycloprop-1-yl carboxylic acids of respective configuration (1S, 2S) and (1R, 2R) prepared according to the method described in "Optical resolution for Chemical compounds" (vol.2, part I / Optical Resolution information center, Manhattan College, Riverdale - NY 10471, USA).

EXEMPLE 53 : (2S,3aS,7aS)-1-[((1S,2S)-2-phénylcycloprop-1-ylcarbonyl]-2-[(2,5-dihydropyrrolin-1-yl)carbonyl]perhydroindole EXAMPLE 53 : (2S, 3aS, 7aS) -1 - [((1S, 2S) -2-phenylcycloprop-1-ylcarbonyl] -2 - [(2,5-dihydropyrrolin-1-yl) carbonyl] perhydroindole EXEMPLE 54 : (2S,3aS,7aS)-1-[((1R,2R)-2-phénylcycloprop-1-ylcarbonyl]-2-[(2,5-dihydropyrrolin-1-yl)carbonyl]perhydroindole EXAMPLE 54 : (2S, 3aS, 7aS) -1 - [((1R, 2R) -2-phenylcycloprop-1-ylcarbonyl] -2 - [(2,5-dihydropyrrolin-1-yl) carbonyl] perhydroindole

   Infrarouge (nujol) νCO (amide) et νC=C = entre 1660 et 1624 cm⁻¹ Infrared (nujol) ν CO (amide) and ν C = C = between 1660 and 1624 cm⁻¹

EXEMPLE 55 : (2S,3aS,7aS)-1-[((1S,2S)-2-phénylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole EXAMPLE 55 : (2S, 3aS, 7aS) -1 - [((1S, 2S) -2-phenylcycloprop-1-yl) carbonyl] -2 - [(1,3-thiazolidin-3-yl) carbonyl] perhydroindole

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % S %S% calculécalculated 68,7268.72 7,347.34 7,287.28 8,348.34 trouvéfind 68,6468.64 7,477.47 7,987.98 8,108.10

EXEMPLE 56 : (2S,3aS,7aS)-1-[((1R,2R)-2-phénylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole EXAMPLE 56 : (2S, 3aS, 7aS) -1 - [((1R, 2R) -2-phenylcycloprop-1-yl) carbonyl] -2 - [(1,3-thiazolidin-3-yl) carbonyl] perhydroindole EXEMPLE 57 : (2S,3aS,7aS)-[(1S,2S)-2-phénylcycloprop-1-yl)carbonyl]-2-[(pyrrol-1-yl)carbonyl]perhydroindole EXAMPLE 57 : (2S, 3aS, 7aS) - [(1S, 2S) -2-phenylcycloprop-1-yl) carbonyl] -2 - [(pyrrol-1-yl) carbonyl] perhydroindole EXEMPLE 58 : (2S,3as,7aS)-[(1R,2R)-2-phénylcycloprop-1-yl)carbonyl]-2-[(pyrrol-1-yl)carbonyl]perhydroindole EXAMPLE 58 : (2S, 3as, 7aS) - [(1R, 2R) -2-phenylcycloprop-1-yl) carbonyl] -2 - [(pyrrol-1-yl) carbonyl] perhydroindole

Microanalyse élémentaire : Elementary microanalysis : C %VS % H %H% N %NOT % calculécalculated 76,2176.21 7,237.23 7,737.73 trouvéfind 75,6875.68 7,117.11 7,417.41

ETUDE PHARMACOLOGIQUE DES DERIVES DE L'INVENTIONPHARMACOLOGICAL STUDY OF THE DERIVATIVES OF THE INVENTION EXEMPLE 59 : Mesure de l'activité anti-prolyl-endopeptidase EXAMPLE 59 Measurement of the anti-prolyl-endopeptidase activity

La méthode de YOSHIMOTO et TSURU (Agr. Biol. Chem., 42, 2417, 1978) a été utilisée. La prolyl-endopeptidase est isolée de Flavobacterium meningosepticum. Le substrat enzymatique est la Z-Gly-Pro-pNitroaniline.The method of YOSHIMOTO and TSURU (Agr. Biol. Chem., 42 , 2417, 1978) was used. Prolylendopeptidase is isolated from Flavobacterium meningosepticum. The enzyme substrate is Z-Gly-Pro-pNitroaniline.

Un mélange de tampon phosphate 0,1 M (pH 7 ; 0,99 ml), de substrat 2 M (0,25 ml) et d'une solution du composé inhibiteur à tester (0,01 ml) est incubé à 37°C durant 5 minutes. Puis 0,1 ml d'une solution de prolylendopeptidase (0,5 U/ml) est ajouté et le mélange est laissé 10 minutes à 37°C. La réaction enzymatique est stoppée par addition de 2 ml d'une solution de Triton X-100-Tampon acétate 1 M (pH 4). Après repos à température ambiante, l'absorbance est mesurée à 410 nm.A mixture of 0.1 M phosphate buffer (pH 7; 0.99 ml), 2 M substrate (0.25 ml) and a solution of the inhibitor compound to be tested (0.01 ml) is incubated at 37 °. C for 5 minutes. Then 0.1 ml of a prolylendopeptidase solution (0.5 U / ml) is added and the mixture is left for 10 minutes at 37 ° C. The enzymatic reaction is stopped by adding 2 ml of a solution of Triton X-100-1 M acetate buffer (pH 4). After standing at room temperature, the absorbance is measured at 410 nm.

Une mesure témoin est réalisée en remplaçant la solution du composé à tester par le même volume de tampon phosphate. Le pourcentage d'inhibition de l'enzyme est calculé à partir de cette mesure témoin. Pour chaque composé testé, la concentration inhibant de 50 % la prolylendopeptidase (IC50) est déterminée.A control measurement is carried out by replacing the solution of the compound to be tested with the same volume of phosphate buffer. The percentage inhibition of the enzyme is calculated from this control measurement. For each compound tested, the concentration inhibiting prolylendopeptidase by 50% (IC50) is determined.

Les composés de l'invention ont été comparés aux deux composés de référence connus pour leur forte activité inhibitrice de la prolylendopeptidase et décrits initialement dans ce but : ONO1603 (EP 345 428) et N-(4-phénylbutanoyl)-L-thiaprolylpyrrolidinéimide (exemple 3 : EP 321 956) appelé ci-dessous ZERIA.The compounds of the invention were compared with the two reference compounds known for their strong prolylendopeptidase inhibiting activity and described initially for this purpose: ONO1603 (EP 345 428) and N- (4-phenylbutanoyl) -L-thiaprolylpyrrolidineimide (example 3: EP 321 956) called ZERIA below.

Les dérivés de l'invention exercent une forte activité inhibitrice de la prolyl-endopeptidase, supérieure aux composés de référence comme l'indique le tableau des IC50 :

Figure imgb0022
Figure imgb0023
 The derivatives of the invention exert a strong inhibitory activity on prolylendopeptidase, superior to the reference compounds as indicated in the table of IC50:
Figure imgb0022
Figure imgb0023

EXEMPLE 60 : EXAMPLE 60 :

La mesure de l'inhibition de la prolyl-endopeptidase a été réalisée in vitro et in vivo dans le cortex cérébral du Rat, grâce à un substrat proche d'un peptide naturellement clivé par la prolyl-endopeptidase, la Thyrotropin-Releasing Hormone (TRH).The measurement of the inhibition of prolyl-endopeptidase was carried out in vitro and in vivo in the cerebral cortex of the Rat, thanks to a substrate close to a peptide naturally cleaved by prolyl-endopeptidase, Thyrotropin-Releasing Hormone (TRH ).

Un extrait de cortex cérébral est préparé en broyant le tissu dans un tampon phosphate (NaH₂PO₄ 25 mM ; DTT 2 mM ; EDTA-2K 0,5 mM) à raison de 5 ml/g.An extract of the cerebral cortex is prepared by grinding the tissue in a phosphate buffer (NaH₂PO₄ 25 mM; DTT 2 mM; EDTA-2K 0.5 mM) at a rate of 5 ml / g.

Après centrifugation, 200 µl de surnageant sont incubés 15 minutes à 37°C dans un volume final de 2,1 ml auquel sont ajoutés 250 µl de substrat (TRH-pNitroaniline) pour une nouvelle incubation de 20 minutes suivie d'une lecture immédiate d'absorbance à 410 nm.After centrifugation, 200 µl of supernatant are incubated for 15 minutes at 37 ° C in a final volume of 2.1 ml to which are added 250 µl of substrate (TRH-pNitroaniline) for a further incubation of 20 minutes followed by immediate reading of absorbance at 410 nm.

Le produit testé est soit ajouté à l'extrait de cortex avant la première incubation (détermination de l'IC50 in vitro) soit administré par voie IP 30 minutes avant la préparation de l'extrait tissulaire.The test product is either added to the cortex extract before the first incubation (determination of the IC50 in vitro) or administered by the IP route 30 minutes before the preparation of the tissue extract.

Dans les conditions du test, les composés de l'invention inhibent fortement la prolyl-endopeptidase du cortex cérébral de Rat tant in vitro qu'après administration in vivo . Cette activité est là encore très supérieure à celle des composés de référence.

Figure imgb0024
Figure imgb0025
 Under the conditions of the test, the compounds of the invention strongly inhibit prolylendopeptidase from the rat cerebral cortex both in vitro and after administration in vivo. Again, this activity is much higher than that of the reference compounds.
Figure imgb0024
Figure imgb0025

EXEMPLE 61 : EXAMPLE 61

La durée d'action des composés vis-à-vis de l'inhibition in vivo de la prolyl-endopeptidase dans le cortex cérébral du Rat a été estimée selon la même méthodologie que dans l'exemple 58, en administrant par voie IP les composés étudiés à divers temps avant la préparation de l'extrait tissulaire. Le temps pour lequel l'effet inhibiteur est égal à 50 % de l'effet maximum (mesuré à 30 minutes) a été calculé (t 1/2).The duration of action of the compounds with respect to the in vivo inhibition of prolylendopeptidase in the cerebral cortex of the Rat was estimated according to the same methodology as in Example 58, by administering the compounds by the IP route. studied at various times before the preparation of the tissue extract. The time for which the inhibitory effect is equal to 50% of the maximum effect (measured at 30 minutes) has been calculated (t 1/2).

De même, la biodisponibilité orale des composés de l'invention a été estimée en les administrant par voie IP ou orale 30 minutes ou 60 minutes avant la mesure de l'effet inhibiteur. L'index de biodisponibilité orale (IBO) a été déterminé en divisant l'effet inhibiteur (%) mesuré après administration orale par celui mesuré après administration IP. Les composés les plus actifs de l'invention exercent leurs effets selon une durée d'action cérébrale bien plus longue que celle des composés de référence et avec une biodisponibilité orale bien plus importante, ce qui leur confère un intérêt thérapeutique prépondérant. dose (mg/kg) t 1/2 IBO ZERIA 30 1 heure 0,30 ONO 1603 30 1 heure <0,30 Exemple 5 15 2 heures 0,40 Exemple 10 30 2 heures 0,40 Exemple 32 2,5 7 heures 0,75 Exemple 50 0,15 7 heures 0,85 Exemple 54 0,6 7 heures 0,80 Exemple 56 0,6 7 heures 0,80 Likewise, the oral bioavailability of the compounds of the invention was estimated by administering them by the IP or oral route 30 minutes or 60 minutes before the measurement of the inhibitory effect. The oral bioavailability index (IBO) was determined by dividing the inhibitory effect (%) measured after oral administration by that measured after IP administration. The most active compounds of the invention exert their effects according to a duration of cerebral action much longer than that of the reference compounds and with a much greater oral bioavailability, which gives them a preponderant therapeutic interest. dose (mg / kg) t 1/2 IBO ZERIA 30 1 hour 0.30 ONO 1603 30 1 hour <0.30 Example 5 15 2 hours 0.40 Example 10 30 2 hours 0.40 Example 32 2.5 7 hours 0.75 Example 50 0.15 7 hours 0.85 Example 54 0.6 7 hours 0.80 Example 56 0.6 7 hours 0.80

COMPOSITION PHARMACEUTIQUEPHARMACEUTICAL COMPOSITION EXEMPLE 62 : Comprimé : Formule de préparation pour 1000 comprimés dosés à 10 mg EXAMPLE 62 Tablet: Preparation Formula for 1000 Tablets Dosed at 10 mg

Composé de l'exemple 1Composed of Example 1 10 g10g Hydroxypropyl celluloseHydroxypropyl cellulose 2 g2 g Amidon de bléWheat starch 10 g10g LactoseLactose 100 g100g Stéarate de magnésiumMagnesium stearate 3 g3 g TalcTalc 3 g3 g

Claims (14)

1/ Procédé de préparation des composés de formule (I) :
Figure imgb0068
 dans laquelle :
   A représente avec les atomes de carbone et d'azote auquel il est attaché l'un quelconque des hétérocycliques suivants :
Figure imgb0069
Figure imgb0070
Figure imgb0071
Figure imgb0072
Figure imgb0073
    B représente avec l'atome d'azote auquel il est attaché l'un quelconque des hétérocycles suivants :
Figure imgb0074
Figure imgb0075
Figure imgb0076
Figure imgb0077
    R₁ représente un groupement alkoxy (C₁-C₆) linéaire ou ramifié, benzyloxy, phénoxy, alkyle (C₁-C₆) linéaire ou ramifié, alkényle (C₁-C₆) linéaire ou ramifié ou cycloalkyle (C₃-C₇), chacun des groupements alkyle, alkényle ou cycloalkyle étant éventuellement substitué par un ou plusieurs groupements, identiques ou différents :
      phényle, naphtyle, cycloalkyle (C₃-C₇), phénylcycloalkyle (C₃-C₇), trifluorométhyle, dicycloalkyle (C₃-C₇) méthylthio,
Figure imgb0078
 (dans lequel R₂ et R₃, identiques ou différents, représentent un atome d'hydrogène, un groupement phényle, benzyle ou cycloalkyle (C₃-C₇) méthyle),
Figure imgb0079
 (dans lequel
      R₄ représente un groupement phényle, cycloalkyle (C₃-C₇) ou dicycloalkyle (C₃-C₇) méthyle,
      R₅ représente un atome d'hydrogène, un groupement phényle, cycloalkyle (C₃-C₇) ou trifluorométhyle),
à la condition que : * lorsque A représente avec les atomes de carbone et d'azote auquel il est attaché un cycle 1,3-thiazolidine,
R₁ représente un groupement alkyle (C₁-C₆) linéaire ou ramifié substitué au moins par l'un quelconque des groupements suivants : - cycloalkyle (C₃-C₇), - phénylcycloalkyle (C₃-C₇), - trifluorométhyle, - (trifluorométhylphényl) méthyle, - dicycloalkyl (C₃-C₇) méthylthio,
Figure imgb0080
Figure imgb0081
 ou bien R₁ représente un groupement phénylcycloalkyle (C₃-C₇) ou
Figure imgb0082
 * lorsque B représente avec l'atome d'azote auquel il est attaché un cycle pyrrolidine,
R₁ représente l'un quelconque des groupements suivants : - terbutoxy, - phénylcyclopropyl, - alkyle (C₁-C₆) linéaire ou ramifié ou alkényle (C₁-C₆) linéaire ou ramifié,
chacun des groupements alkyle ou alkényle étant toujours substitué par au moins un groupement dicycloalkyl (C₃-C₇) méthyle, dicycloalkyl (C₃-C₇) méthylthio,
Figure imgb0083
 ou par deux groupements cycloalkyle (C₃-C₇), - trifluorométhylalkyle (C₁-C₆) linéaire ou ramifié, trifluorométhylalkényle (C₁-C₆) linéaire ou ramifié éventuellement substitués par un ou plusieurs groupements phényle ou cycloalkyle (C₃-C₇), * lorsque A représente avec les atomes de carbone et d'azote auquel il est attaché un cycle 2,3-dihydroindole et B représente avec l'atome d'azote auquel il est attaché un cycle pyrrolidine, alors R₁ est différent d'un groupement 3-phénylpropyl, leurs énantiomères, diastéréoisomères et épimères ainsi que leurs sels d'addition à un acide pharmaceutiquement acceptable,
   caractérisé en ce que l'on fait réagir un acide de formule (II), dont on a éventuellement séparé les isomères par une technique classique de séparation :
Figure imgb0084
 dans laquelle A a la même signification que dans la formule (I) et R′₁ représente un groupement alkoxy (C₁-C₆) linéaire ou ramifié ou benzyloxy,
   sur une amine de formule (III), dont on a éventuellement séparé les isomères par une technique classique de séparation, selon une technique de couplage peptidique :
Figure imgb0085
 dans laquelle B a la même signification que dans la formule (I),
   pour conduire au composé de formule (I/a), cas particulier des composés de formule (I) :
Figure imgb0086
 dans laquelle A, B et R′₁ ont la même signification que précédemment,
   que l'on déprotège, si on le souhaite, par une technique classique de déprotection,
pour conduire à l'amine de formule (IV) :
Figure imgb0087
 dans laquelle A et B ont la même signification que dans la formule (I),
que l'on fait réagir avec un acide de formule (V) en présence d'un agent de couplage classique de la synthèse peptidique :

        HO₂C-R˝₁   (V)

dans laquelle :
   X représente un atome d'halogène,
   R˝₁ a la même signification que R₁ à l'exception du cas où R₁ représente R′₁
   pour conduire au composé de formule (I/b), cas particulier des composés de formule (I) :
Figure imgb0088
 dans laquelle A, B et R˝₁ ont la même signification que précédemment,
   dérivés de formule (I/a) et (I/b) que l'on purifie, le cas échéant, par une technique classique de purification, dont on sépare, si on le souhaite, les isomères par une technique classique de séparation et que l'on transforme, si nécessaire, en leurs sels d'addition à un acide pharmaceutiquement acceptable. 1 / Process for preparing the compounds of formula (I):
Figure imgb0068
 in which :
A represents with the carbon and nitrogen atoms to which it is attached any of the following heterocyclics:
Figure imgb0069
Figure imgb0070
Figure imgb0071
Figure imgb0072
Figure imgb0073
 B represents with the nitrogen atom to which it is attached any one of the following heterocycles:
Figure imgb0074
Figure imgb0075
Figure imgb0076
Figure imgb0077
 R₁ represents a linear or branched (C₁-C₆) alkoxy, benzyloxy, phenoxy, linear or branched (C₁-C₆) alkyl, linear or branched (C₁-C₆) alkenyl or cycloalkyl (C₃-C₇) group, each of the alkyl groups, alkenyl or cycloalkyl being optionally substituted by one or more groups, identical or different:
phenyl, naphthyl, cycloalkyl (C₃-C₇), phenylcycloalkyl (C₃-C₇), trifluoromethyl, dicycloalkyl (C₃-C₇) methylthio,
Figure imgb0078
 (in which R₂ and R₃, identical or different, represent a hydrogen atom, a phenyl, benzyl or cycloalkyl (C₃-C₇) methyl group),
Figure imgb0079
 (in which
R₄ represents a phenyl, cycloalkyl (C₃-C₇) or dicycloalkyl (C₃-C₇) methyl group,
R₅ represents a hydrogen atom, a phenyl, cycloalkyl (C₃-C₇) or trifluoromethyl group),
provided that : * when A represents with the carbon and nitrogen atoms to which it is attached a 1,3-thiazolidine ring,
R₁ represents a linear or branched (C₁-C₆) alkyl group substituted at least by any of the following groups: - cycloalkyl (C₃-C₇), - phenylcycloalkyle (C₃-C₇), - trifluoromethyl, - (trifluoromethylphenyl) methyl, - dicycloalkyl (C₃-C₇) methylthio,
Figure imgb0080
Figure imgb0081
 or else R₁ represents a phenylcycloalkyl group (C₃-C₇) or
Figure imgb0082
 * when B represents with the nitrogen atom to which it is attached a pyrrolidine ring,
R₁ represents any one of the following groups: - terbutoxy, - phenylcyclopropyl, - linear or branched (C₁-C₆) alkyl or linear or branched (C₁-C₆) alkenyl,
each of the alkyl or alkenyl groups always being substituted by at least one dicycloalkyl (C₃-C₇) methyl, dicycloalkyl (C₃-C₇) methylthio group,
Figure imgb0083
 or by two cycloalkyl groups (C₃-C₇), - linear or branched trifluoromethylalkyl (C₁-C₆), linear or branched trifluoromethylalkenyl (C₁-C₆) optionally substituted by one or more phenyl or cycloalkyl (C₃-C₇) groups, * when A represents with the carbon and nitrogen atoms to which it is attached a 2,3-dihydroindole ring and B represents with the nitrogen atom to which it is attached a pyrrolidine ring, then R₁ is different from a group 3-phenylpropyl, their enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid,
characterized in that an acid of formula (II) is reacted, from which the isomers have optionally been separated by a conventional separation technique:
Figure imgb0084
 in which A has the same meaning as in formula (I) and R′₁ represents a linear or branched (C₁-C₆) alkoxy or benzyloxy group,
on an amine of formula (III), the isomers of which have optionally been separated by a conventional separation technique, according to a peptide coupling technique:
Figure imgb0085
 in which B has the same meaning as in formula (I),
to lead to the compound of formula (I / a), special case of the compounds of formula (I):
Figure imgb0086
 in which A, B and R′₁ have the same meaning as above,
that we deprotect, if desired, by a conventional deprotection technique,
to lead to the amine of formula (IV):
Figure imgb0087
 in which A and B have the same meaning as in formula (I),
which is reacted with an acid of formula (V) in the presence of a conventional coupling agent for peptide synthesis:

HO₂C-R˝₁ (V)

in which :
X represents a halogen atom,
R˝₁ has the same meaning as R₁ except for the case where R₁ represents R′₁
to lead to the compound of formula (I / b), special case of the compounds of formula (I):
Figure imgb0088
 in which A, B and R˝₁ have the same meaning as before,
derivatives of formula (I / a) and (I / b) which are purified, if necessary, by a conventional purification technique, from which the isomers are separated, if desired, by a conventional separation technique and that it is converted, if necessary, into their addition salts with a pharmaceutically acceptable acid. 2/ Procédé de préparation des composés de formule (I) selon la revendication 1 tels que A représente avec les atomes de carbone et d'azote auquel il est attaché un cycle 2-azabicyclo[2.2.2]octane, leurs énantiomères, diastéréoisomères et épimères ainsi que leurs sels d'addition à un acide pharmaceutiquement acceptable. 2 / A process for preparing the compounds of formula (I) according to claim 1 such that A represents with the carbon and nitrogen atoms to which it is attached a 2-azabicyclo [2.2.2] octane ring, their enantiomers, diastereoisomers and epimers and their addition salts with a pharmaceutically acceptable acid. 3/ Procédé de préparation des composés de formule (I) selon la revendication 1 tels que A représente avec les atomes de carbone et d'azote auquel il est attaché un cycle 2-azabicyclo[2.2.1]heptane, leurs énantiomères, diastéréoisomères et épimères ainsi que leurs sels d'addition à un acide pharmaceutiquement acceptable. 3 / A process for preparing the compounds of formula (I) according to claim 1 such that A represents with the carbon and nitrogen atoms to which it is attached a 2-azabicyclo [2.2.1] heptane ring, their enantiomers, diastereoisomers and epimers and their addition salts with a pharmaceutically acceptable acid. 4/ Procédé de préparation des composés de formule (I) selon la revendication 1 tels que A représente avec les atomes de carbone et d'azote auquel il est attaché un cycle perhydroindole, leurs énantiomères, diastéréoisomères et épimères ainsi que leurs sels d'addition à un acide pharmaceutiquement acceptable. 4 / A process for preparing the compounds of formula (I) according to claim 1 such that A represents with the carbon and nitrogen atoms to which it is attached a perhydroindole ring, their enantiomers, diastereoisomers and epimers as well as their addition salts to a pharmaceutically acceptable acid. 5/ Procédé de préparation des composés de formule (I) selon la revendication 1 tels que B représente avec l'atome d'azote auquel il est attaché un cycle pyrrolidine, leurs énantiomères, diastéréoisomères et épimères ainsi que leurs sels d'addition à un acide pharmaceutiquement acceptable. 5 / A method of preparing the compounds of formula (I) according to claim 1 such that B represents with the nitrogen atom to which it is attached a pyrrolidine ring, their enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid. 6/ Procédé de préparation des composés de formule (I) selon la revendication 1 tels que B représente avec l'atome d'azote auquel il est attaché un cycle 1,3-thiazolidine, leurs énantiomères, diastéréoisomères et épimères ainsi que leurs sels d'addition à un acide pharmaceutiquement acceptable. 6 / A method of preparing the compounds of formula (I) according to claim 1 such that B represents with the nitrogen atom to which it is attached a 1,3-thiazolidine ring, their enantiomers, diastereoisomers and epimers as well as their salts d addition to a pharmaceutically acceptable acid. 7/ Procédé de préparation des composés de formule (I) selon la revendication 1 tels que B représente avec l'atome d'azote auquel il est attaché un cycle 2,5-dihydropyrrole, leurs énantiomères, diastéréoisomères et épimères ainsi que leurs sels d'addition à un acide pharmaceutiguement acceptable. 7 / A process for preparing the compounds of formula (I) according to claim 1 such that B represents with the nitrogen atom to which it is attached a 2,5-dihydropyrrole ring, their enantiomers, diastereoisomers and epimers as well as their salts d addition to a pharmaceutically acceptable acid. 8/ Procédé de préparation des composés de formule (I) selon l'une quelconque des revendications 1 ou 5 tels que R₁ représente un groupement phénylcyclopropyl, leurs énantiomères, diastéréoisomères et épimères ainsi que leurs sels d'addition à un acide pharmaceutiguement acceptable. 8 / A process for preparing the compounds of formula (I) according to any one of claims 1 or 5 such that R₁ represents a phenylcyclopropyl group, their enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid. 9/ Procédé de préparation du composé de formule (I) selon la revendication 1 qui est le 2-aza-[(2-phénylcycloprop-1-yl)carbonyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo[2.2.2] octane, ses énantiomères, diastéréoisomères et épimères ainsi que ses sels d'addition à un acide pharmaceutiquement acceptable. 9 / A method of preparing the compound of formula (I) according to claim 1 which is 2-aza - [(2-phenylcycloprop-1-yl) carbonyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [ 2.2.2] octane, its enantiomers, diastereoisomers and epimers as well as its addition salts with a pharmaceutically acceptable acid. 10/ Procédé de préparation du composé de formule (I) selon la revendication 1 qui est le 2-aza-2-[(2-phénylcycloprop-1-yl)carbonyl]-3-[(pyrrolidin-1-yl)carbonyl]bicyclo [2.2.1]heptane, ses énantiomères, diastéréoisomères et épimères ainsi que ses sels d'addition à un acide pharmaceutiquement acceptable. 10 / A method of preparing the compound of formula (I) according to claim 1 which is 2-aza-2 - [(2-phenylcycloprop-1-yl) carbonyl] -3 - [(pyrrolidin-1-yl) carbonyl] bicyclo [2.2.1] heptane, its enantiomers, diastereoisomers and epimers as well as its addition salts with a pharmaceutically acceptable acid. 11/ Procédé de préparation du composé de formule (I) selon la revendication 1 qui est le 1-[(2-phénylcycloprop-1-yl)carbonyl]-2-[(pyrrolidin-1-yl)carbonyl]perhydro-indole, ses énantiomères, diastéréoisomères et épimères ainsi que ses sels d'addition à un acide pharmaceutiquement acceptable. 11 / A method for preparing the compound of formula (I) according to claim 1 which is 1 - [(2-phenylcycloprop-1-yl) carbonyl] -2 - [(pyrrolidin-1-yl) carbonyl] perhydro-indole, its enantiomers, diastereoisomers and epimers as well as its addition salts with a pharmaceutically acceptable acid.
EP92402631A 1991-09-27 1992-09-25 Nitrogen containing bicyclic derivatives, method for their preparation and pharmaceutical compositions containing them Expired - Lifetime EP0541407B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9111893 1991-09-27
FR9111893A FR2681864B1 (en) 1991-09-27 1991-09-27 NOVEL BICYCLIC NITROGEN DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.

Publications (2)

Publication Number Publication Date
EP0541407A1 true EP0541407A1 (en) 1993-05-12
EP0541407B1 EP0541407B1 (en) 1997-02-26

Family

ID=9417343

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92402631A Expired - Lifetime EP0541407B1 (en) 1991-09-27 1992-09-25 Nitrogen containing bicyclic derivatives, method for their preparation and pharmaceutical compositions containing them

Country Status (13)

Country Link
US (2) US5286732A (en)
EP (1) EP0541407B1 (en)
JP (1) JPH07119212B2 (en)
AT (1) ATE149165T1 (en)
AU (1) AU651495B2 (en)
CA (1) CA2079185A1 (en)
DE (1) DE69217613T2 (en)
DK (1) DK0541407T3 (en)
ES (1) ES2101059T3 (en)
FR (1) FR2681864B1 (en)
GR (1) GR3023444T3 (en)
HK (1) HK113597A (en)
ZA (1) ZA927381B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672598A1 (en) * 1991-02-11 1992-08-14 Adir NOVEL N-MYRISTOYLTRANSFERASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2703050B1 (en) * 1993-03-24 1995-04-28 Adir New nitrogenous bicyclic derivatives, process for their preparation and the pharmaceutical compositions containing them.
US6025355A (en) 1997-05-19 2000-02-15 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
DE19616509A1 (en) * 1996-04-25 1998-01-15 Asta Medica Ag New specific immunophilin ligands as anti-asthmatics, immunosuppressants
FR2748026B1 (en) * 1996-04-26 1998-06-05 Adir NOVEL METALLOPROTEASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
GB2460976B (en) * 2005-03-24 2010-02-17 John Marcell Davis Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
CA2786777A1 (en) * 2010-01-07 2011-07-14 Akron Molecules Gmbh Obesity small molecules
EP3031458A1 (en) 2014-12-09 2016-06-15 Iproteos S.L. Use of 1-[(2-phenylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole in the treatment of schizophrenia-associated cognitive deficits

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0320753A2 (en) * 1987-12-15 1989-06-21 Hoechst Aktiengesellschaft Derivatives of cyclic aminoacids, their preparation, compounds containing them, and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0813740B2 (en) * 1987-02-28 1996-02-14 麒麟麦酒株式会社 Antiamnestic
JPH0742309B2 (en) * 1987-11-30 1995-05-10 キッセイ薬品工業株式会社 Thiazolidine derivative
JPH01250370A (en) * 1987-12-23 1989-10-05 Zeria Pharmaceut Co Ltd New amino acid imide derivatives, manufacturing methods and uses
US5053414A (en) * 1988-04-08 1991-10-01 Ono Pharmaceutical Co., Ltd. Heterocyclic compounds
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
WO1991018891A1 (en) * 1990-06-04 1991-12-12 Pfizer Inc. Aromatic pyrrolidine and thiazolidine amides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0320753A2 (en) * 1987-12-15 1989-06-21 Hoechst Aktiengesellschaft Derivatives of cyclic aminoacids, their preparation, compounds containing them, and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 112, 1990, Columbus, Ohio, US; abstract no. 682e, 'Prolyl endopeptidase-inhibiting thiazolidines for treatment of amnesia and dementia' page 66 ; & JP 01143897, KISSEI (06.06.89) *
JOURNAL OF ENZYME INHIBITION vol. 5, no. 1, 1991, CHUR, CH pages 51 - 75 NAOKI HIGUCHI ET AL. 'Synthesis and inhibitory activity of acyl-peptidyl-pyrrolidine derivatives toward post-proline cleaving enzyme; a study of subsite specificity' *

Also Published As

Publication number Publication date
AU2533492A (en) 1993-04-01
JPH07119212B2 (en) 1995-12-20
GR3023444T3 (en) 1997-08-29
EP0541407B1 (en) 1997-02-26
US5286732A (en) 1994-02-15
FR2681864A1 (en) 1993-04-02
ES2101059T3 (en) 1997-07-01
FR2681864B1 (en) 1995-03-31
ATE149165T1 (en) 1997-03-15
DK0541407T3 (en) 1997-08-25
HK113597A (en) 1997-08-29
CA2079185A1 (en) 1993-03-28
DE69217613D1 (en) 1997-04-03
US5384322A (en) 1995-01-24
JPH05262730A (en) 1993-10-12
AU651495B2 (en) 1994-07-21
DE69217613T2 (en) 1997-09-25
ZA927381B (en) 1993-04-26

Similar Documents

Publication Publication Date Title
EP0528734B1 (en) Thiazolidin-2,4-dione derivatives, process for their preparation and pharmaceutical compositions containing them
EP0618193B1 (en) Nitrogen containing bicyclic derivatives as prolyl-endopeptidase inhibitors
EP0031741A1 (en) Substituted imino-acids, process for their preparation and their use as enzyme inhibitors
CA2555216C (en) Novel azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same
EP0462884A1 (en) TRH derivatives, their preparations and pharmaceutical compositions containing them
FR2679903A1 (en) DERIVATIVES OF N - SULFONYL INDOLINE CARRYING AMIDIC FUNCTION, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
EP0580502A1 (en) 3-(Hydroxybenzylidenyl)-indoline-2-ones and pharmaceutical compositions containing them
EP0406119B1 (en) New peptide derivatives, process of their preparation and pharmaceutical compositions containing them
EP0541407B1 (en) Nitrogen containing bicyclic derivatives, method for their preparation and pharmaceutical compositions containing them
FR2711139A1 (en) Novel 1,2,3,4-tetrahydronaphthalene derivatives, process for their preparation and pharmaceutical compositions containing them
EP0004494B1 (en) Derivatives of 1,3-dihydro-3-(1-(2-(2,3-dihydro-1,4-benzodioxin-2-yl)2-hydroxyethyl)piperidin-4-yl)2h-indol-2-on, process for their preparation, their use as medicaments and pharmaceutical compositions containing them
EP0556119B1 (en) Pyrrolidine derivatives substituted in the 3-position with a saturated or insaturated fatty acid group, process for their preparation and pharmaceuticals with thromboxane A2 inhibiting activity containing them
EP0549407A1 (en) Novel pyrrolidine derivatives, process for their preparation and pharmaceutical compositions containing them
EP0486385B1 (en) Imidazole derivatives, process for their fabrication and pharmaceutical compositions containing them
EP1598350B1 (en) Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis
JP2526084B2 (en) Novel thiazolidine derivative
EP1383762B1 (en) Tetrahydropyridyl-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same
FR2953515A1 (en) NOVEL HEXAHYDROCYCLOPENTA [B] PYRROLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
EP0434560B1 (en) New derivatives of substituted aminoacids, process for their preparation and pharmaceutical compositions containing them
EP1476434A2 (en) Pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same
EP1383761A1 (en) Phenyl- and pyridyl-piperidines with tnf activity
FR2738567A1 (en) ALPHA-PHENYLPIPERIDINE-1-PROPANOL DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2823750A1 (en) New 1-(heterocyclyl-alkyl)-4-(phenyl or pyridyl)-tetrahydropyridines, are tumor necrosis factor-alpha synthesis inhibitors useful for treating autoimmune or inflammatory diseases or pain
JPWO1991018877A1 (en) Novel arylalkanoylamine derivatives and medicines containing the same
JPS6165884A (en) Bicyclic compounds, manufacturing methods and drugs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920930

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19951019

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

REF Corresponds to:

Ref document number: 149165

Country of ref document: AT

Date of ref document: 19970315

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69217613

Country of ref document: DE

Date of ref document: 19970403

ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: 72225

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 19970523

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19970228

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2101059

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3023444

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20000711

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20000712

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20000717

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20000721

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20000727

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20000814

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20000822

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20000823

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20000920

Year of fee payment: 9

Ref country code: GB

Payment date: 20000920

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20000925

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20000926

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20000928

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20000929

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010925

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010925

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010925

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010925

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010925

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010926

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010930

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010930

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010930

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

BERE Be: lapsed

Owner name: ADIR ET CIE

Effective date: 20010930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020501

EUG Se: european patent has lapsed

Ref document number: 92402631.3

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20010925

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020531

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20020401

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20020331

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20020401

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20021011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050925